


















Synthesis and biological function of fucose  
in Plasmodium falciparum 
 













Aquesta tesi doctoral està subjecta a la llicència Reconeixement- NoComercial – 
CompartirIgual  4.0. Espanya de Creative Commons. 
 
Esta tesis doctoral está sujeta a la licencia  Reconocimiento - NoComercial – CompartirIgual  
4.0.  España de Creative Commons. 
 
This doctoral thesis is licensed under the Creative Commons Attribution-NonCommercial-





Synthesis and biological  
function of fucose in  
Plasmodium falciparum 
 
Sílvia Sanz Sender 
Director: Luis Izquierdo 
 
 
Línia de recerca: Salut Internacional 
Programa de Doctorat en Medicina 
 
























“Si vols arribar ràpid camina sola, 




TABLE OF CONTENTS 
 
LIST OF ABREVIATIONS .............................................................................................................. 1 
INTRODUCTION........................................................................................................................... 9 
 Malaria ............................................................................................................................... 9 
1.1. Malaria burden ....................................................................................................... 9 
1.2. Disease .................................................................................................................... 10 
1.3. Control and elimination ...................................................................................... 11 
1.3.1. Prevention .......................................................................................................... 11 
1.3.2. Diagnostic ........................................................................................................ 12 
1.3.3. Treatment ......................................................................................................... 12 
 Plasmodium falciparum ............................................................................................... 14 
2.1. P. falciparum life cycle ........................................................................................ 15 
2.1.1. From the mosquito to the liver ................................................................... 16 
2.1.2. Red blood cell invasion and sexual commitment ................................. 18 
2.1.3. Parasite development in the mosquito vector ....................................... 21 
 Glycobiology ...................................................................................................................23 
3.1. General aspects ....................................................................................................23 
3.2. Glycosylation precursors and glycosyltransferases .....................................25 
3.2.1. UDP–Glucose (UDP-Glc): ............................................................................. 27 
3.2.2. UDP–N–acetylglucosamine (UDP-GlcNAc): ........................................... 27 
3.2.3. GDP–mannose (GDP-Man): .......................................................................28 
3.2.4. GDP–fucose  (GDP-Fuc): .............................................................................28 
3.3. Types of glycosylation in P. falciparum ..........................................................28 
3.3.1. GPI-anchors .....................................................................................................29 
3.3.2. N-glycosylation .............................................................................................. 31 
3.3.3. C-mannosylation ...........................................................................................32 
3.3.4. O-glycosylation ..............................................................................................32 
HYPOTHESIS AND OBJECTIVES ............................................................................................ 41 
RESULTS ...................................................................................................................................... 45 
 Article 1 ............................................................................................................................ 45 
 Article 2 ............................................................................................................................59 
 Unpublished work ......................................................................................................... 73 
DISCUSSION ............................................................................................................................... 101 
CONCLUSIONS ......................................................................................................................... 111 
ANNEX ......................................................................................................................................... 115 
 Summarized catalan version ..................................................................................... 115 
 Other contributions .................................................................................................... 135 
BIBLIOGRAPHY ......................................................................................................................... 143 





LIST OF ABREVIATIONS 
α-gal – α-galactose 
AAL - Aleuria aurantia lectin 
ACT – Artemisinin-based Combined Therapy 
Alg – Asparagine linked glycosylation 
AMA – 1 – Apical Membrane Antigen – 1  
Asn – Asparagine  
C – Carbon  
CDPK3 – Calcium dependent protein kinase 3  
CMP – Cytidine monophosphate 
CQ – Chloroquine  
CSA – Chondroitin Sulphate A 
CSP – Circumsporozoite Protein 
CTRP – Circumsporozoite and TRAP related protein 
Cys – Cysteine  
Dol–P – Dolichol-Phosphate 
Dol-P-Man – Dolichol-phosphate-mannose 
Dol-P-P-GlcNAc – dolichol pyrophosphate-N-acetylglucosamine 
DPM1 - Dolichol-phosphate mannose polypeptide 1 
DTT - Dichloro-diphenyl-trichloroethane 
EBA 175 - Erythrocyte binding antigen 175 
ECM - Extracellular Matrix 
EEF – Exoerythrocytic Form 
EGF – Epidermal Growth factor 
2 
 
ER – Endoplasmic Reticulum 
EtN-P - Ethanolamine – Phospahte 
Fru – Fructose 
Fru6P – Fructose-6-phosphate 
FS - GDP – L – Fucose synthase 
Fuc – Fucose  
GAG – Glycosaminoglycan 
Gal – Galactose  
GALE – UDP-Glucose 4-epimerase 
GalNAc – N- acetylgalactosamine 
Gal1P – Galactose-1-phosphate 
GDP – Guanine diphosphate 
GDP-Fuc – GDP-Fucose 
GDP-Man – GDP-Mannose 
GFPT – Glucosamine – fructose – 6 – phosphate aminotransferase 
GK – Galactokinase 
Glc – Glucose  
Glc1P – Glucose-1-phosphate 
Glc6P – Glucose-6-phosphate 
GlcA – Glucoronic acid 
GlcN - Glucosamine 
GlcNAc – N – acetylglucosamine  
GlcNAc1P – N-acetylglucosamine-1-phosphate 
GlcNAc6P – N-acetylglucosamine-6-phosphate  
GlcN6P – Glucosamine-6-phosphate 
3 
 
Gly - Glycine 
GMD – GDP – mannose 4,6 – dehydratase 
GNA – Glucosamine – phosphate N – acetyltransferase 
GpA – Glycophorin A 
GPI – Glycosylphosphatidylinositol 
G6PD – Glucose – 6 – phosphate dehydrogenase 
G6PI – Glucose-6-phosphate isomerase 
H – Hydrogen  
HA – Hyaluronic Acid 
HK – Hexokinase   
hpi – hours post invasion 
HSPG – heparin sulphate proteoglycan 
IPTi – Intermitent Preventive Treatment in infants  
IPTp – Intermitent Preventive Treatment in pregnancy  
IRS – Indoor Residual insecticide Sprays 
KC – Kupffer Cell 
KO – Knockout 
LLIN – Long Lasting Insecticide-treated Nets 
LLO – Lipid linked oligosaccharide 
Man – Mannose 
Man1P – Mannose-1-phosphate 
Man6P – Mannose-6-phosphate 
MPG – Mannose – 1 – Phosphate guanyltransferase 
MPI – Mannose – 6 – phosphate isomerase 
MSP – Merozoite Surface Protein 
4 
 
N - Nitrogen 
O – Oxygen  
OH – hydroxyl  
OST - Olygosaccharyltransferase 
P - Phosphate 
PAGM – Phosphoacetylglucosamine  mutase  
PCR – Polymerase chain reaction 
PfEMP1 – Plasmodium falciparum erythrocyte membrane protein 1  
PGM – Phosphoglucomutase  
PI – Phosphatidylinositol  
PIESP1 – parasite-infected erythrocyte surface protein 1 
PM – Peritrophic Matrix 
PMM – Phosphomannomutase  
PoFUT – Protein o-fucosyltransferase  
PV – Parasitophorous Vacuole 
RBC – Red Blood Cell 
RDT – Rapid Diagnostic Test 
S – Sulfur  
Ser – Serine 
Sia – Sialic Acid 
SMC – Seasonal Malaria Chemoprevention 
SP – Sulphadoxine Pyrimethamine 
SPATR - Secreted Protein with Altered Thrombospondin Repeat domain 
TLP – TRAP like Protein 
Thr – Threonine 
5 
 
TRAMP - Thrombospondin-Related Apical Membrane Protein 
TRAP – Thrombospondin Related Anonymous Protein 
TREP – TRAP like protein 
Trp - Tryptophan 
TRSP – Thrombospondin-related sporozoite protein 
TSR – Thrombospondin Type 1 Repeat 
UAP – UDP – N – acetylglucosamine pyrophosphorylase  
UDP – Uridine diphosphate 
UDP-Gal – UDP-Galactose 
UDP-Glc – UDP-Glucose 
UDP-GlcNAc – UDP-N-acetylglucosamine 
UEA-I – Ulex europaeus agglutinin I 
UGP – UTP – glucose – 1 – phosphate urydiltransferase  
USP – UDP – sugar pyrophosphorylase 
vWF-A - von Willebrand factor A 
WHO – World Health Organization 













1.1. Malaria burden 
Malaria kills a child in Africa every 2 minutes. Malaria is one of the most important 
parasitic diseases that affect humans, threatening almost half of the world population. It is 
caused by an apicomplexan protozoan parasite of the genus Plasmodium that is 
transmitted by female mosquitoes of the genus Anopheles. There are five different species 
of Plasmodium that cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, 
P. ovale and P. knowlesi1. More than 400 species of Anopheles mosquitoes exist around the 
world but only 70 are capable of transmitting malaria. Due to their propensity of feeding in 
humans, abundance, longevity or a combination of all these factors, 40 different species 
have been described as dominant vector species2,3. 
Eliminate P. falciparum and P. vivax malaria became the most important challenge 
to control the disease because they are responsible for the majority of malaria cases. P. 
falciparum is present in tropical, subtropical and warm temperature regions, and it is the 
predominant species in Africa4. It is responsible for most malaria deaths and the severity is 
more acute4,5. P. vivax is more widely distributed than P. falciparum, however it carries a 
lower risk of fatal outcome, approximately only 1% of malaria deaths4,6. The lack of a robust 
and continuous culture technique of this parasite hinders the study of its biology, 
transmission and pathogenesis, even though some improvements have been done7. 
Moreover, P. vivax elimination is more challenging due to the relapse of the dormant liver-
stage hypnozoites, a reservoir of infection8. 
Although there has been a significant decrease in the incidence of malaria since the 
beginning of the millennium, the disease still kills 1200 people a day. According to the latest 
estimates from the World Health Organization (WHO), there were 241 million new cases of 
malaria and 429.000 deaths worldwide in 2015. Globally, the African region accounted for 
most of the malaria cases (88%). Despite the situation is still dramatic, there has been a 
drastic decrease trend from 20006.  
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In areas where the transmission is high, children under five and women in their first 
pregnancy are more vulnerable to malaria than other population with acquired immunity. 
The continuous contact with Plasmodium parasites confers the so called acquired immunity, 
making the majority of adults refractory to the disease9. In low transmission areas, where 
this acquired immunity is lower, all ages are at risk of infection. Refugees are also very 
vulnerable due to the poor living conditions. Non-immune individuals going to endemic 
areas or travelers visiting tropical Africa are also very susceptible to the disease10. 
 
Figure 1. Countries with outgoing transmission of malaria, 2013. Reproduced from World Malaria Report, WHO, 201411. 
1.2. Disease 
Seven to fifteen days after the infected Anopheles bite, the initial symptoms of 
malaria may appear and the disease can be classified as uncomplicated or severe. When 
an infection with Plasmodium parasites occurs, it can lead to a very wide range of 
symptoms: from absent or very weak manifestations to a severe illness or even death.  
Uncomplicated or mild malaria symptoms are nonspecific and can comprise general 
discomfort, headache and fever as well as mild anemia and a palpable spleen. When treated 
fast enough with antimalarial drugs, mortality of uncomplicated malaria patients is very low1. 
The principal manifestations of severe malaria are cerebral malaria, renal failure, severe 
jaundice and pulmonary edema. Severe malaria is dependent on transmission intensity, it 
occurs in young children in high malaria transmission areas, and in people of all ages in low 
transmission areas12.  
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Malaria in pregnancy has an overwhelming effect on mother and baby’s health and 
it is an important case of maternal and infant mortality and morbidity13. Natural acquired 
immunity decreases during pregnancy, particularly during first and second pregnancies9. In 
high transmission areas malaria in pregnancy is associated with spontaneous abortion, 
premature delivery, stillbirth, severe maternal anemia low birth weight, and neonatal 
death14. In low transmission areas the manifestations may include severe disease and 
mother or fetus death15. 
1.3. Control and elimination 
A great number of countries are working towards malaria elimination16. In the last 
15 years, the number of countries with less than 1.000 malaria cases has increased from 13 
to 33 and the WHO European Region reported zero indigenous cases of malaria in 2015. 
Nevertheless, it is known that only 15 countries accounted for the 80% of the cases, being 
countries in sub-Saharan Africa the ones suffering a higher mortality and disease burden. 
The Democratic Republic of Congo and Nigeria together represent the 35% of the global 
total of estimated malaria deaths. A decrease in the incidence in these countries is urgently 
needed to improve the global progress towards malaria elimination5. 
Malaria can be prevented and treated using different cost-effective interventions. 
The main ones comprise vector control, chemoprevention, and appropriate case 
management (including diagnostic and treatment)17. 
1.3.1. Prevention 
Vector control is an essential component of prevention. Its main objective is to 
diminish the vectorial capacity of local mosquito population. The vector control strategies 
with a higher impact comprise indoor residual insecticide sprays (IRSs) and long lasting 
insecticide-treated nets (LLINs). These tools contribute to malaria control and local malaria 
elimination in many malaria-endemic regions18. Anopheles resistance to existing pesticides 
is emerging, so there is a need of developing a broader range of insecticides with novel 
mechanisms of action19,20. Another key issue is the need for the development of new 
strategies to act on vector species not effectively targeted by currently used tools21. 
Nevertheless, the most difficult challenge to be faced is the design of new approaches to 
permanently reduce the high vectorial capacities of dominant malaria vectors in Sub-
Saharan Africa18 
Chemoprevention is the use of antimalarial drugs or medicines for prophylaxis and 
preventive treatment in risk groups. The objective of chemoprevention is to prevent malaria 
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infection by maintaining therapeutic drug levels in the blood. WHO currently recommends 
the Intermittent Preventive Treatment in pregnancy (IPTp), the Intermittent Preventive 
Treatment in infants (IPTi), and the Seasonal Malaria Chemoprevention (SMC) in endemic 
areas. IPTp consists in delivering Sulphadoxin-Pyrimethamin (SP) to all women in their first 
or second pregnancy in malaria endemic areas. IPTi (SP) is given to infants younger than 12 
months and SMC (amodiaquine and SP) is recommended in malaria seasonal transmission 
areas to all children under 6 years5. 
The absence of financially lucrative, high-income markets makes the investment in 
malaria prevention, treatment, and vaccine development to massively depend on public 
and philanthropic funding22. Many vaccine trials have become unsuccessful for different 
reasons including antigen polymorphism, poor immunogenicity, and inadequate 
understanding of protein function in the parasite life cycle23. Nevertheless, effective vaccines 
would be an excellent tool towards malaria eradication. The malaria vaccine RTS,S/AS01, 
which provides a modest protection against clinical malaria, was recently licensed and 
approved for use by the European Medicine Agency5. WHO’s Strategic Advisory Group of 
Experts on Immunization has recommended a large-scale pilot implementation of the 
malaria vaccine in parts of three to five countries6.  
1.3.2. Diagnostic 
A prompt and reliable diagnosis is another important tool to effectively determine 
if someone is infected with malaria parasite, treat accordingly and, contribute to disease 
control. Sensitive and specific malaria diagnosis is required to significantly reduce morbidity 
and death. Giving malaria treatment specifically to those patients with confirmed presence 
of parasites will contribute to diminish the emergence and expansion of drug resistances. 
Malaria Rapid Diagnostics Tests (RDT) detect specific antigens produced by malaria 
parasites that are present in blood. These kits are an alternative to diagnosis based on 
microscopy, especially in the places where good quality microscopy services are difficult to 
find. These two tools, RDTs and microscopy, are the first option for malaria diagnosis in the 
field, while the detection of parasites by molecular techniques (Polymerase Chain Reaction 
(PCR)) are only to be considered for epidemiological research and surveys24. 
1.3.3. Treatment  
The first-line treatment for malaria has evolved with time considering new 
discoveries and the appearance of drug resistances. Chloroquine (CQ) was implemented 
by WHO as first-line treatment, but unfortunately the first resistance isolates were confirmed 
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at the beginning of the 1960’s after treatment failures in Venezuela and Thailand at the late 
50’s25. After the emergence of CQ resistance, alternative drugs such as SP, mefloquine, 
amodiaquine and quinine were used as monotherapies, leading again to the emergence of 
resistant strains26–28. In 1972 Youyou Tu re-designed a protocol to obtain artemisinin from 
Artemisa Annua. This compound, by entering the parasite food vacuole, is able to damage 
the parasite hemoglobin catabolism and kill the parasite29. She received a Nobel Prize for 
this discovery in 2015. This component has become part of the current WHO treatment 
recommendation in endemic areas with the Artemisinin – based Combination Therapy 
(ACT)30, to try to avoid the emergence of artemisinin resistance. 
Combined therapies consist in a combination of artemisinin derivatives with  longer-
acting antimalarials that have a different mechanism of action17. Artemisinin derivatives clear 
parasite from the blood very fast and are also active against sexual stages31, while the 
longer-acting antimalarial cleans remaining parasites and provides protection against the 
development of resistances to artemisinin derivatives. Unfortunately, resistance to 
artemisinin recently emerged in Western Cambodia32,33 and it has been confirmed in four 
other countries: Lao People’s Democratic republic, Myanmar, Thailand, and Vietnam. In 
most of these places, the patients still recover since they are treated with an ACT containing 
the partner drug that is still effective. But in Cambodia-Thailand border, P. falciparum has 
become resistant to almost all currently available antimalarial drugs, leading to a reversion 
of what has been achieved in the past years34. The emergence of new resistances stresses 




 Plasmodium falciparum 
Malaria parasites were first described by Alphonse Laveran in 188035. He started to 
follow the pigment (i.e. hemozoin) of malaria described by Meckel in 1847 and later by 
Virchow and Frerichs35. It had been observed that the spleen of malaria patients contained 
this malaria pigment so Laveran tried to identify it in fresh unstained blood of patients. He 
observed it in leucocytes and red blood cells (RBC). He realized that he was seeing different 
intraerythrocytic forms (Figure 2), which he first thought they were outside the erythrocytes. 
He concluded that he had found a parasitic protozoan, which he called Oscillaria malariae, 
that later was renamed as Haemamoeba malariae, the present P. falciparum35. Laveran was 
awarded the Nobel Prize for Medicine in 1907 for his discoveries36. 
It was in 1897 when William 
MacCallum, while studying the 
mosquito stages of avian malaria, found 
some flagellated structures that fused 
with non-motile bodies forming a 
vermicular, what we now know as 
ookinetes37. He suggested that he was 
observing sexual reproduction that 
should correlate in mammals and 
defined that flagellated forms were 
male gametes and non-motile forms 
corresponded to female gametes, being 
the vermicule the zygote38. Ronald Ross, 
during his time in India, discovered that 
avian malaria parasite Plasmodium relictum was transmitted by culicine mosquitoes and 
suggested that the same could be true for the human malaria parasite. However, it was not 
until 1898, when he moved to Sierra Leone, that he proved that human malaria parasites 
were certainly transmitted by anopheline mosquitoes36. 
In 1934 chloroquine (CQ) was discovered by the german scientist Hans Andersag, 
but only in 1943 was established as an effective and safe antimalarial. Three years after the 
CQ discovery, the insecticidal properties of Dichloro-diphenyl-trichloroethane (DTT) were 
observed by Paul Muller, who received a Nobel Prize in 1948. This finding pushed the WHO 
(created in 1948) to launch a malaria eradication campaign. It was so effective that between 
1955 and 1972 many countries were certified as malaria-free by this organization. Within 
Figure 2. Malaria parasites (Haemamoeba malariae) observed and 
drawn by Alphonse Laveran. published in Comptes Rendus de 
l’Academie des Sciences, 24 October of 1881 (From Sergent & 




this period, the first cases of malaria resistance against CQ were reported25. Between 1967 
and 1981 the People’s Republic of China initiated a program to find new drugs for malaria. 
This project contributed to the discovery of artemisinin and derivatives, for which Youyou 
Tu won a Nobel Prize in 201529. Nowadays ACT is the recommended first line treatments. 
The sequencing of P. falciparum 3D7 clone genome in 200239,40 and the later 
completion of other Plasmodium species sequencing41,42 have opened the door to new 
opportunities for further studies leading to the discovery of new drugs and vaccines to fight 
malaria43. 
2.1. P. falciparum life cycle 
P. falciparum has a complex life cycle that includes important stages in two different 
hosts: a mosquito and a human. The transmission between the human and the mosquito 
host also involves the transition between asexual and sexual forms of the parasites. P. 
falciparum life cycle starts when an infected female Anopheles mosquito inoculates 
sporozoites into the human host during a blood meal. The parasites migrate through the 
skin reaching the circulation and then the liver. In the liver, the sporozoites invade a 
hepatocyte and, after development inside the cell, a hepatic schizont is formed. After 
approximately a week the schizont bursts and thousands of merozoites are released into 
the blood circulation. These pre-erythrocytic merozoites invade RBCs and undergo 
repeated asexual multiplication cycles44. A small percentage of these parasites differentiate 
to sexual male and female gametocytes. These sexual forms will be uptaken by another 
female Anopheles mosquito when feeding on an infected human45. Gametocytes will go 
through fertilization and maturation in the mosquito midgut, forming an infective ookinete 
that migrates through the midgut wall to the hemocele evolving to an oocyst. Inside oocysts 
thousands of sporozoites are formed. After sporozoite maturation the oocyst breaks and 
sporozoites travel to the mosquito salivary glands where they attach getting ready to be 




Figure 3. Life cycle of the parasite Plasmodium falciparum. (A) When a parasite-infected female mosquito feeds on a human, 
it injects sporozoites. These sporozoites travel to the liver, where they develop producing merozoites which will invade red 
blood cells. A subset of infected red blood cells develops into female and male gametocytes. (B) When a mosquito bites the 
infected human, it takes up blood containing gametocytes, which develop into gametes in the mosquito midgut. The gametes 
fuse in the insect's gut to form a zygote. The zygote in turn develops into the ookinete, which crosses the wall of the mosquito 
gut and forms a sporozoite-filled oocyst. When the oocyst bursts, mature sporozoites migrate to the mosquito's salivary 
glands, and the process begins again. Reproduced from Wirth, D.F., Nature, 200244. 
2.1.1. From the mosquito to the liver 
A female infected mosquito inoculates approximately 20 to 200 sporozoites into 
the human skin after a bite. The injected saliva also contains anticoagulants and vasodilators 
to facilitate blood meal and digestion. Most of the sporozoites are injected into the dermis 
and not directly to the blood circulation47,48. A great proportion of these sporozoites show 
a robust forward gliding motility in an apparently random direction at an average speed of 
1-2 µm/s49. Sporozoites move until they find a blood vessel and reach the circulatory system. 
However, some sporozoites remain in the dermis retained by anti-sporozoite antibodies48. 
Some sporozoites can also reach the lymphatic vessels and be baited in the lymph nodes 
where most are phagocytized. Interestingly, a few of them are able to differentiate into 
exoerythrocytic stages in the lymph nodes46,49. 
Once sporozoites reach the circulatory system, they travel rapidly through the blood 
vessels and arrive to the liver sinusoids (Figure 4). Sporozoites target the liver very 
specifically and they can be found in the hepatocytes just a few minutes after entering the 
blood circulation50. This suggests the presence of a specific interaction between parasite 
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and host cell molecules. Sporozoites liver targeting is mediated by the binding of the 
Circumsporozoite Protein (CSP) to the Heparan Sulphate Proteoglycans (HSPG)51.  
Another important sporozoite surface protein, the Thrombospondin Related 
Anonymous Protein (TRAP), is also involved in target cell identification52. CSP and TRAP 
interplay with hepatocytes and, while CSP has an active role in the attachment, TRAP plays 
a role during internalization53. These two proteins recognize distinct cell-type specific 
surface proteoglycans, not only on hepatocytes but also on Kupffer cells (KCs) and on 
stellate cells, two cell subpopulations in the liver. It has been proposed that the 
proteoglycans from the Extracellular Matrix (ECM) of stellate cells are the principal 
candidates for sporozoite targeting in the liver sinusoid51,54.  
Sporozoites invade 
hepatocytes and then initiate the 
intrahepatocytic cycle (Figure 4). They 
cross the liver sinusoidal barrier 
targeting KC or endothelial cells55. In 
the liver they then migrate traversing 
various hepatocytes, finally reaching 
one for definitive invasion, forming the 
parasitophorous vacuole (PV) and 
starting replication56. Sporozoites use 
gliding motility to traverse liver (and 
dermis) cells. However, the mechanism 
that triggers the commitment to the 
invasion of the target hepatocyte is not 
clear57. Plasmodium parasites, as other 
Apicomplexa, use the so-called gliding 
motility for migration through tissues 
and host-cell invasion. Is a form of 
substrate-dependent locomotion, in 
which myosin is anchored to an 
internal membrane complex and 
linked to actin-associated adhesins, translocating it and leading the parasite forward. The 
actin – myosin motor that drives this type of motility is called glideosome58. 
Six to eight days after sporozoite invasion of the hepatocytes, thousands of new 
exoerythrocytic merozoites are generated1. Data describing this specific stage of the 
Figure 4. Sporozoite arrest in the liver. Once the sporozoites (green) 
reach the liver sinusoids, they glide over the endothelium and 
interact with (HSPGs) from hepatocyte and stellate cells. They then 
cross the sinusoidal layer possibly through Kupffer Cells (KC). 
Reproduced from Prudêncio et al., Nat.Rev.Microbiol, 200646. 
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parasite cycle is limited. The sporozoite usually lies close to the nucleus of the infected 
hepatocyte along the intrahepatocytic development. During the first 24 hours after invasion 
the sporozoite-specific organelles are dismantled. The parasite then goes to an schizogonic 
stage, growing to a larger size than the original hepatocyte and generating thousands of 
merozoites that will infect RBCs59. The last step of the liver stage consists in exiting the 
hepatocyte and reaching the bloodstream again, in a process also not very well understood. 
It has been reported that merozoites are released by the formation of merozoites-filled 
vesicles called merosomes. Merosomes plasma membrane has its origin on the hepatocyte 
cell membrane, making more difficult to be recognized by Dendritic or Kupffer cells and 
contributing to a final safe passage to the blood circulation60. 
2.1.2. Red blood cell invasion and sexual commitment 
After being released from the merosome, merozoites recognize, attach, and enter 
the erythrocytes avoiding exposure to host antibodies61. This starts the asexual cycle of the 
parasite. The asexual blood stages of Plasmodium parasites are responsible for the 
symptoms of the disease. Merozoites, with an approximately size of 1.6 µm long and 1 µm 
wide, enclose all the machinery needed to eggress from the merosome and, in the case of 
intraerythrocytic merozoites, from the RBC. They also contain mediators to attach to a new 
erythrocyte, invade it, and restart multiplication (Figure 3). Merozoites have a polarized 
morphology and specialized apical organelles – rophtries, micronemes and dense granules 
– to effectively enter the RBC62.  
The first step during RBC invasion is the attachment of the merozoite to the 
erythrocyte through weak interactions. Different merozoite surface proteins (MSP) have 
been related to this initial process63,64. After this, the merozoite reorientates connecting the 
anterior apex towards the RBC membrane61. The next stage of the invasion process consists 
in the formation of a tight junction between the merozoite and the erythrocyte. This is a 
critical step, since it provides a firm support for the merozoite to drive into the RBC65,66. In 
the last step, proteins from the rophtries involved in the induction of the PV are injected in 
the RBC as the parasite glides into it. The PV is formed from the erythrocyte membrane 




Figure 5. Merozoite invasion of erythrocytes. Invasion involves an initial "long distance" recognition of surface receptors (A) 
followed by a reorientation process whereby these low - affinity contacts are maintained. Once the apical end is adjacent to 
the erythrocyte surface (B), a tight junction is formed involving high-affinity ligand-receptor interactions. This thight junction 
then moves from the apical to posterior pole (C and D) by gliding motility. The surface coat is shed at the moving junction by 
a serine protease, or “sheddase”. Upon reaching the posterior pole, adhesive proteins at the junction are also proteolytically 
removed (E), in a process that facilitates RBC membrane resealing. By this process, the parasite does not actually penetrate 
the membrane but invades it in a manner that creates a PV. Reproduced from Cowman et al., Cell, 200661. 
 Once the merozoite has invaded the RBC, the asexual development requires 
approximately 48 hours in P. falciparum69. During this cycle the parasite undergoes three 
main morphological states: rings, trophozoites and schizonts (Figure 6)70. Through the 
process, the parasite reshapes the erythrocyte membrane by exporting a large number of 
proteins. The ring stage (0-24 hours post invasion (hpi)) is characterized by a thin discoidal 
or cup-shaped form. It has a 
thick cytoplasm edge where the 
principal parasite organelles can 
be found. The parasite feeds on 
a small disc at the surface of the 
parasite, the cytostome, and 
digests hemoglobin 
accumulating haemozoin 
crystals in the pigment or 
digestive vacuole62. When 
entering the trophozoite stage 
(24-36 hpi),  the metabolic 
activity of the parasite increases 
and the trafficking of proteins to 
the RBC membrane intensifies71–
73. The ingestion of RBC 
Figure 6. Giemsa staining of intraerythrocytic blood stages of P. falciparum in 
culture. Ring stages can be observed between 0 and 24 hours post invasion. 
Trophozoites occur between 24 and 36 hours and schizonts develop from 36 
to 48 hours after invasion. Adapted from Radfar et al., Nat Proc, 200969. 
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cytoplasm takes place until the final stages of the cycle, generating more haemozoin crystals 
deposited in the pigment vacuole. The schizont stage (36-48 hpi) starts after multiple 
nuclear division and results in the formation of about 16-32 merozoites. Each nuclei forms 
a merozoite that gets oriented closer to the RBC surface. The erythrocyte membrane 
ruptures and the merozoites egress being released into the bloodstream. They will be then 
ready to start the asexual cycle again invading a fresh erythrocyte62.  
A small proportion , approximately 1%74, of the blood stage parasites differenciate 
into male and female sexual forms, the gametocytes, which are essential for parasite 
transmission to the mosquito vector. Gametocyte commitment occurs at a not yet defined 
point before schizont nuclear division, since merozoites derived from the same schizont 
become either all gametocytes or continue as asexual parasites75. In vitro, the exposure of 
parasites to different stress factors, such as high parasitemia or drug treatment, is correlated 
with an increment of commitment rate. However, how environment in natural infection 
triggers gametocytogenesis is unknown, although some studies indicate that commitment 
may be stochastic45. After gametocytogenesis starts, gametocyte development takes 
approximately 10 to 12 days. Gametocytes go through five different stages (I-V) that are 
distinct microscopically (Figure 7).  
 
Figure 7. The stages of gametocyte development in P. falciparum. Development of a mature P. falciparum gametocyte occurs 
over 10 to 12 days and is divided into five morphologically distinct stages. Adapted from Josling et al., Nat. Rev. Microbiol., 
201545. 
In P. falciparum, stage I gametocytes are very similar to young asexual trophozoites, 
while stage II start to elongate in a D shape. Stage III have slightly rounded ends whereas 
stage IV are thiner and have pointed ends. Stage V male and female can be distinguished 
from each other since female are more elongated and curved than the thicker males45,76. 
During their development, only early (stage I) and late (stage V) gametocytes are circulating 
in the peripheral blood whereas II-IV stage gametocytes are accumulated in the bone 
marrow to avoid clearance by the spleen77. Circulating stage V gametocytes are ready for 
uptake in a mosquito blood meal again. 
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Gametocytogenesis is an essential step in the parasite life cycle required for 
transmission from human to mosquito. Given the low number of asexual parasites that 
develop into gametocytes, sexual development is considered one of the critical bottlenecks 
in the parasite life cycle that can be targeted for transmission blocking therapies. The 
majority of antimalarials are not effective against mature gametocytes. Therefore, even if 
asexual parasites responsible for the malaria symptoms are killed, the gametocytes involved 
in transmission can remain in circulation over a month78. Primaquine is an approved 
antimalarial drug very active against mature gametocytes. However it can cause haemolytic 
anemia in people with glucose-6-phosphate dehydrogenase (G6PD) defficency, a highly 
prevalent deficit in malaria endemic areas79,80. New therapies affecting asexual and sexual 
blood parasites could greatly contribute to malaria eradication. 
2.1.3. Parasite development in the mosquito vector 
Stage V male and female gametocytes circulate through the peripheral blood and 
are taken up by a mosquito during a blood meal. Soon after ingestion, gametocytes are 
subjected to environmental changes such as a drop in temperature, pH increase, and the 
exposure to xanthurenic acid that cause the egression and maturation of gametocytes into 
male and female gametes in the mosquito midgut81. Male gametocytes undergo three 
different rounds of DNA replication producing eight flagellated sexually competent cells. 
The release of these 8 gametes is called exflagellation. After this process, fertilization takes 
place and female and male gametes fuse to form a diploid zygote, a proces that can occur 
within an hour.  
After male and female nuclei fuse, the nucleus and microtubules elongate and the 
cell grows through a polarization process. This is essential for ookinete formation. Ookinetes 
are elongated and motile cells with specialized secretory organelles, the micronemes, that 
contain proteins involved in motility, cell traversal, and invasion. Ookinetes use gliding 
motility to leave the blood meal and penetrate through the peritrophic matrix (PM) that 
encloses the blood meal and acts as a physical barrier82 (Figure 8). Ookinete maturation is 
required for chitinase activation, an enzyme needed to cross the PM. CDPK3 (Calcium 
dependent protein kinase 3) and CTRP (Circumsporozoite and TRAP related protein) are 
proteins involved in ookinete motility and infectivity. Their disruption generates mutants 
unable to invade the mosquito midgut epithelium or to produce oocysts83,84. After 
breaching the PM the ookinete penetrates the apical end of the midgut epithelium (Figure 
8)85. Ookinete migration through the epithelial cell activates cell changes from a motile form 
to a sessile condition, starting transformation to oocyst86.  
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Oocyst development is the only extracellular stage of the parasite life cycle where 
there is parasite multiplication. The parasite goes through a dozen nuclear divisions 
becoming a multinucleated parasite form, since cytokinesis does not take place in paralel 
with karyokinesis. The cytoplasm starts partitioning into sporoblasts finally resulting in a 
mature oocyst full of haploid sporozoites. During oocyst growth, a capsule that surrounds 
the forming sporozoites is made. This capsule is a bilayered structure with a wall derived 
from the mosquito basal lamina and an inner membrane covered with a dense coat of CSP, 
a protein that also covers oocyst and salivary gland sporozoite surfaces87,88. Oocyst 
development is fully completed after approximately 14 days and thousands of sporozoites 
bud asynchronously from oocysts’s sporoblasts. Mature sporozoites are released in the 
hemocoel (Figure 8) and circulate through mosquito tissues. When sporozoites pass by the 
basal lamina of salivary glands they recognize mosquito receptors that allow salivary gland 
adhesion. Sporozoites cross this basal lamina and invade the salivary gland, being TRAP 
one of the key proteins for invasion and attachment89. After this process, the sporozoite 
finishes its development in the mosquito host and it is ready to be injected in the human 
dermis again90.  
 
 
Figure 8. Malaria parasite development in the mosquito vector. Plasmodium gametocytes are ingested by Anopheles 
mosquitoes during a blood meal. Male and female gametes emerge from gametocytes and fertilization occurs to form the 
zygote. The zygote undergoes meiosis and transforms into the ookinete. Ookinetes first breach the peritrophic matrix 
surrounding the blood meal, followed by entry into the apical end of the midgut epithelium and traversal of several midgut 
epithelial cells. Ookinetes exit the midgut epithelium through the basal end and transform into sessile oocysts. The oocyst 
undergoes extensive growth and completes its development within 10–14 days, resulting in the production of thousands of 
sporozoites. Sporozoites egress from the oocyst and travel in the hemolymph before attaching to the basal side of the salivary 
gland acinar cells. Sporozoites traverse the acinar cells and enter the ducts of the salivary glands. The salivary gland 





3.1. General aspects 
Glycobiology is a broad field that comprises the study of any molecule containing 
carbohydrates as part of its structure. Therefore, it includes the study of carbohydrate 
metabolism and glycoconjugate (glycoprotein and glycolipid) structures. It has become a 
well – established area of study in the last two decades. 
Carbohydrates (often called sugars) are molecules composed of carbon (C), 
hydrogen (H) and oxigen (O). Monosaccharides are the most basic examples of 
carbohydrates and are the basic building blocks from which all bigger carbohydrate chains 
are made. Monosaccharides are classified according to the number of carbon atoms in a 
molecule. Thus, pentoses are the monosaccharides that have 5 carbons, hexoses the ones 
that contain 6 carbons, and so on. Two monosaccharides with the same molecular formula 
may be different esterioisomers, due the chirality or asymmetry of their carbon atoms. Free 
monosacharides can exist in open or in ring form, but when forming part of a 
polysaccharide they are in the ring form. Glucose (Glc), N-acetylglucosamine (GlcNAc), 
galactose (Gal), N-acetylgalactosamine (GalNAc), mannose (Man) and fucose (Fuc) are 
some of the most common monosachharides (Figure 9). Linkage of different 
monosaccharides form the so-called oligosaccharides or polysaccharides. Monosaccharide 
residues within a carbohydrate may contain non-carbohydrate substituent moieties, such 
as phosphate, sulfate or other functional groups. Monosaccharides can be covalently bound 
through different linkages (α or β) to any of the several C positions on other 
monosaccharides in a carbohydrate chain. Therefore, polysaccharide chains present an 
enormous number of possible combinations. Nevertheless, not all the possible 
combinations have been described in nature91. Carbohydrates are important as energetic 
source, but they also play roles in other important biological processes including cell–cell 
adhesion, cell–matrix adhesion, cell–signaling, 
protein folding quality control and host–
pathogen interactions, among others.  
 
Figure 9. Ring and symbolic representations of common 
monosaccharides. Each symbol represents a specific 
monosaccharide. Glc, D-glucose; GlcNAc, N-acetyl-D-
glucosamine; Gal, D-galactose; GalNAc, N-acetyl-D-
galactosamine; Man, D-mannose; Fuc, L-fucose. 
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Glycoconjugates are defined as compounds that contain a saccharide (mono or 
polysaccharide) covalently linked to another type of molecules like proteins or lipids, 
forming glycoproteins or proteoglycans and glycolipids, respectively. In eukaryotic cells 
there are different types of glycans covalently attached to proteins or lipids, among which 
we find N–linked oligosaccharides, linked to asparagine (Asn) amino acids; O–linked 
oligosaccharides, associated to serine (Ser) or threonine (Thr) residues; 
glycosylphosphatidylinositol (GPI) molecules that anchor proteins in cell surfaces and consist 
of a glycan chain linked to phosphatidylinositol groups and; other types of glycosylation, as 
shown in Figure 1092. 
 
Figure 10. Glycans present in higher eukaryotes. a) N-linked glycans on glycoproteins are covalently bound to Asn. b) O-
linked glycans are found covalently linked to Ser or Thr residues on glycoproteins and mucins. c) Glycosphingolipids consist 
on the lipid ceramide linked to one or more sugars. d) GPI-linked proteins are anchored to the membrane by a glycan 
covalently linked to phosphatidylinositol. e) Glycosaminoglycans can occur as free chains (as in hyaluronan case) or as covalent 
complexes with proteoglycan core proteins. f) Proteoglycan. g) Cytoplasmic or nuclear proteins contain O-GlcNAc. Glc, 
glucose; Gal, galactose; Man, mannose; GlcNAc, N-acetylglucosamine; GalNAc, N-acetylgalactosamine; GlcA, glucuronic acid; 
Fuc, fucose; Xyl, xylose; Sia, sialic acid. Adapted from Fuster et al., Nat. Rev. Cancer, 200592. 
25 
 
The biological roles of glycans are very diverse. Some of them are essential for 
development, growth or survival of an organism, while alterations on others produce 
different syndromes or diseases92,93. Still, in many cases the function that they play at a 
cellular or whole organism level it is not known.  
Protozoan parasites synthesize several glycoconjugates and glycan binding proteins 
(or lectins) for protection and to interact and respond to changes in their environment. 
Host–parasite interactions are crucial for parasite survival and many of these interactions 
take place through carbohydrate recognition94. Glycoconjugates coat parasite surfaces with 
carbohydrates that are generally different from the host ones. This glycocalyx, critical for 
parasite virulence and survival, masks proteins from the host immune system protecting the 
parasite against the host defenses95. The glycome is the complete set of glycosylations that 
an organism or cell produces at a certain time point. A parasite glycome description is an 
enormous challenge which, together with the determination of the biological significance 
of the different glycosylations, may contribute to the description of host parasite 
interactions in parasitic diseases94. Hence, the study of parasite glycobiology is a promising 
field that may lead to the identification of novel parasiticidal drugs for carbohydrate related 
targets or to the discovery of new vaccine candidates or diagnostic tools.  
P. falciparum has different glycosylated proteins and lectins that play important 
roles in virulence of the parasite, attachment and invasion of the host cell. Among these, 
we find CSP, TRAP, erythrocyte binding antigen 175 (EBA 175) and PfEMP1 (P. falciparum 
erythrocyte membrane protein 1)96. Some of the carbohydrate containing receptors on host 
cells that bind to parasite proteins comprise Glycophorin A (GpA), Glycosaminoglycans 
(GAGs), Chondroitin Sulfate A (CSA) and Hyaluronic Acid (HA). Describing these protein-
glycan interactions could open new ways to target them and inhibit parasite development97. 
 
3.2. Glycosylation precursors and glycosyltransferases 
Sugar nucleotides are activated forms of monosaccharides. These sugar nucleotide 
precursors are monosaccharides covalently linked to nucleotides and are used by specific 
glycosyltransferases as donors for glycosylation reactions. The most common sugar 
nucleotide donors present in eukaryotic cells are listed in Table 1. In general, two main 
metabolic routes for the biosynthesis of sugar nucleotides have been described. They can 
be synthesized by a salvage pathway that involves phosphorylation by a kinase and a further 
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pyrophosphorylase activation, or by a de novo route that consists in the bioconversion of 
an existing sugar or sugar nucleotide91. 
Table 1. Activated sugar donors. Adapted from Varki et al., Essentials of glycobiology, 200991 
Sugar Activated form 
Glucose (Glc) 
] UDP-sugar 
(Uridine diphosphate – 
sugar) 
Galactose (Gal) 
N – acetylcglucosamine 
(GlcNAc) 
Glucuronic acid  
(GlcA) 
Xylose (Xyl) 
Mannose (Man) ] GDP-Sugar 
(Guanosine 
diphosphate – sugar)  Fucose (Fuc) 
Sialic acid (Sia) 
] CMP-Sia 
(Cytidine 
monophosphate - Sia) 
 
Glycosylation reactions consist in the transfer of the monosaccharide component of 
a sugar nucleotide to a specific acceptor. Glycosyltransferases are the enzymes responsible 
for the biosynthesis of glycans, by adding monosaccharides to specific positions on specific 
molecules98. Acceptors can be oligosaccharides, proteins (specific aminoacids), lipids or 
even DNA. The majority of the glycosyltransferase enzymes are located in the Endoplasmic 
Reticulum (ER) – Golgi pathway, since most of the glycosylation reactions take place in the 
cellular secretory pathway. Glycosyltransferases act sequentially and the product of a 
reaction acts as acceptor for the following one, generating linear and/or branched 
polysaccharides91. 
Identification and quantification of sugar nucleotides in the different P. falciparum 
stages could contribute to outline the parasite glycosylation profile and its glycome, since 
these precursors would be substrates for the parasite glycosyltransferases94. A brief 
explanation of the different sugar nucleotides present, or predicted to be present, in P. 




Figure 11. Sugar nucleotide biosynthesis pathways in Plasmodium falciparum. Activated sugars, used, or predicted to be used 
for glycoconjugate biosynthesis, are underlined. Carbohydrates, taken up from the medium or salvaged, are circled. Sugar 
nucleotide donor fates are indicated and they are in italics when glycosylations have not been proved to be present in the 
parasite. Discontinuous arrow depicts a predicted enzymatic activity that can not be identified in P. falciparum genome. HK, 
Hexokinase, EC 2.7.1.1; PGM, Phosphoglucomutase, EC 5.4.2.2; UGP, UTP–glucose–1–phosphate urydiltransferase EC 2.7.7.9; 
USP, UDP–sugar pyrophosphorylase, EC 2.7.7.64; G6PI, Glucose-6-phosphate isomerase; GFPT, Glucosamine–fructose–6–
phosphate aminotransferase, EC 2.6.1.16; GNA, Glucosamine–phosphate N–acetyltransferase, EC 2.3.1.4; PAGM, 
Phosphoacetylglucosamine mutase, EC 5.4.2.3; UAP, UDP–N–acetylglucosamine pyrophosphorylase, EC 2.7.7.23; MPI, 
Mannose–6–phosphate isomerase, EC 5.3.1.8; PMM, Phosphomannomutase, EC 5.4.2.8; MPG, Mannose–1–Phosphate 
guanyltransferase, EC2.7.7.13; GMD, GDP–mannose 4,6–dehydratase, EC 4.2.1.47; FS, GDP– L– fucose synthase, EC 1.1.1.271. 
Glc, Glucose; Glc6P, Glucose-6-phosphate; Glc1P, Glucose-1-phosphate; UDP-Glc, UDP-Glucose; Fru6P, Fructose-6-
phosphate; GlcN, Glucosamine; GlcN6P, Glucosamine-6-phosphate; GlcNAc6P, N-acetylglucosamine-6-phosphate; 
GlcNAc1P, N-acetylglucosamine-1-phosphate; UDP-GlcNAc, UDP-N-acetylglucosamine; Man, Mannose; Man6P, Mannose-6-
phosphate; Man1P, Mannose-1-phosphate; GDP-Man, GDP-Mannose; GDP-Fuc, GDP-Fucose Adapted from Cova et al. Malar. 
J, 201599. 
3.2.1. UDP–Glucose (UDP-Glc): 
Considering the conserved enzymatic activities in P. falciparum genome, the 
synthesis of UDP–Glc from Glc-6-P is catalyzed by phosphoglucomutase (PGM) followed 
by UTP–glucose–1–P uridyltransferase (UGP). The fate of P. falciparum UDP-Glc has not 
been studied in depth. The first evidence of UDP-Glc incorporation was demonstrated by 
Couto et al. when the sugar nucleotide was used as a donor for a glycosylation reaction 
with two different ceramides100. Another possible function for this sugar nucleotide is the 
addition of a glucose residue on O–fucosylated Thrombospondin type I repeat (TSR) 
domains101,102. 
3.2.2. UDP–N–acetylglucosamine (UDP-GlcNAc): 
UDP–GlcNAc is the sugar donor for all GlcNAc transferases. In P. falciparum two 
main ways of synthesizing UDP-GlcNAc have been described. The de novo pathway consists 
in the interconversion of Fru–6P to UDP–GlcNAc by the action of different enzymes, via the 
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so-called amino sugar pathway (Figure 11). All of them, except glucosamine–6-phosphate 
N–acetyltransferase (GNA), have been identified in the parasite genome. The salvage 
pathway for UDP-GlcNAc has been demonstrated and, through a hexokinase activity (HK), 
GlcN is salvaged and phosphorylated to GlcN – 6P. After the phosphorylation, GlcN – 6P 
follows the same route as in the de novo pathway99,103. In P. falciparum, UDP–GlcNAc is the 
sugar nucleotide donor in the GPI-anchor biosynthesis, predicted to be essential for parasite 
survival and infectivity. This sugar nucleotide is also used by Alg (Asparagine linked 
glycosylation) genes, involved in the N-glycosylation of Plasmodium parasites104,105. 
3.2.3. GDP–mannose (GDP-Man): 
GDP-Man is the activated form of mannose. It can be synthesized by salvaging Man 
or via a de novo route, from Fru-6P (Figure 11). Both biosynthetic pathways are conserved 
in P. falciparum106 genome. The salvage pathway requires a phosphorylation of a Man 
residue to Man-6P by a hexokinase and then follows the same route as the de novo 
pathway. The presence of the GDP-Man salvage pathway was demonstrated through the 
incorporation of [3H]-Man into GPI-anchors in the blood stages of the parasite103,107. Man 
residues are present in parasite GPI-anchors108, but remarkably mannose is not present  in 
P. falciparum N–glycans104,105. This monosaccharide is also required for the C-mannosylation 
of tryptophan residues through a carbon-carbon bond, a modification recently described 
in Plasmodium sporozoites102.  
3.2.4. GDP–fucose  (GDP-Fuc): 
The activated form of fucose is the sugar nucleotide GDP-Fuc. The biosynthetic de 
novo pathway of this sugar nucleotide consists in the bioconversion of GDP-Man to GDP-
Fuc through the actions of two different enzymes: a GDP-mannose 4,6-dehydratase (GMD) 
and a GDP-L-fucose synthase (FS). Homologues of this synthetic route are conserved in P. 
falciparum genome as well as in other Plasmodium species106. However, obvious candidates 
for the salvage pathway are absent in the parasite genome. The conservation of a protein 
O-fucosyltransferase 2 (PoFUT2) in the parasite genome suggests the usage of this sugar 
nucleotide in P. falciparum. Disruption in GDP-Fuc de novo biosynthetic pathway in 
Trypanosoma brucei resulted in growth arrest of the parasite, showing the importance of 
this precursor in other protozoan parasites109. 
3.3. Types of glycosylation in P. falciparum 





GPI-anchors are glycolipid moieties that usually anchor proteins to the surface of 
cells. GPI-anchors are assembled through a sequential multistep pathway on a 
phosphatidylinositol lipid in the ER110. After the synthesis, GPIs can be covalently attached 
to the carboxyl terminus of proteins. The 
structure of the GPI-anchor core in higher 
eukaryotes consists of a 
phospahtidylinositol, a glycan generally 
comprising one glucosamine and three 
mannose residues, and a terminal 
phosphoethanolamine110. The P. 
falciparum GPI-anchor structure has been 
described and its glycan core sequence 
may have an extra Man residue, being 
(Manα1-2)Manα1-2Manα1-6Manα1-
4GlcN (Figure 12)107,108.  
 
GPI-anchor synthesis is a complex process that starts in the cytoplasmic face of the 
ER and ends in the ER lumen (Figure 13)99. The first step of the process consists in the 
transfer of a GlcNAc residue from a UDP-GlcNAc to Phosphatidylinositol (PI) to give a 
GlcNAc-PI111. The responsible for this step is the PIG-A enzyme of which a homolog is found 
in P. falciparum112. After some steps, the GPI-anchor intermediate flips to the luminal face 
of the ER membrane. The next steps in the process consist in the addition of the different 
Man residues. They are added by four different GPI mannosyltransferases and using 
Dolichol-phosphate-mannose (Dol-P-Man) as sugar nucleotide donor. GDP-Man is 
required for the synthesis of Dol-P-Man. Genes for the addition of the first three Man can 
also be identified in the parasite genome, but no candidate for the fourth gene has been 
found112. The attachment of the proteins to P. falciparum GPI-anchor structure happens via 
the Ethanolamine – Phospahte (EtN-P) group present in the third Man residue113. 
 
Figure 12. Proposed structure of P. falciparum GPI-anchors. The 
fatty acids and their molar proportions are indicated. 




Figure 13.  Biosynthetic scheme for GPI-anchor biosynthesis in P. falciparum. DPM1, Dolichol-phosphate mannosyltransferase 
polypeptide 1; PIG-A, phosphatidylinositol N-acetylglucosaminyl-transferase; PIG-L, N-acetylglucosaminyl 
phosphatidylinositol deacetylase; PIG-W, Inositol acyltransferase; PIG-M, GPI mannosyltransferase I; PIG-V, GPI 
mannosyltransferase II; PIG-B, GPI mannosyltransferase III; Unidentified gene, GPI mannosyltransferase IV. Man, Mannose; 
GlcN, Glucosamine, GlcNAc, N-acetylglucosamine. Adapted from Cova et al., Malar J, 201599. 
The proteins to be attached to the GPI-structure present a C-terminal signal peptide 
required for GPI-anchor replacement. The loss of this signal in GPI-anchored proteins, such 
as CSP, blocks GPI attachment and impedes the surface localization of the protein114. 
GPI-anchors are the main glycoconjugates described in the blood stages of P. 
falciparum103,115 and anchor critical proteins in the parasite plasma membrane115. Different 
essential parasite proteins, such as MSP1 or MSP2 are GPI-anchored to the merozoite 
surface, strongly suggesting that the disruption of the GPI biosynthetic pathway in the 
parasite would inhibit parasite growth115. GPI-anchors are also present in gametocytes, 
ookinete and sporozoite parasite forms115. Proteins p25 and p28, two of the most important 
proteins in the surface of ookinetes, are anchored to the parasite membrane via a GPI-
anchor116. In the sporozoite stage, CSP is also attached to the surface by a GPI-structure117. 
GPI-anchors have also been described as toxins able to induce cytokine expression in 
macrophages, being partially responsible for malaria associated pathogenesis108,118. 
Schofield et al. synthesized a synthetic malarial GPI-glycan showing that it was 
immunogenic in rodents, making it a candidate for an anti-toxin vaccine119. GPI’s from other 





The production of N–glycans requires a lipid-linked oligosaccharide (LLO) precursor 
that is covalently attached to a protein Asn residue through a N–glycosidic bond. LLO 
synthesis begins in the cytoplasmic face of the ER when a GlcNAc residue from UDP-GlcNAc 
is transferred to the lipid–like precursor Dolichol–P (Dol-P), forming dolichol 
pyrophosphate-N-Acetylglucosamine (Dol-P-P-GlcNAc). Once synthesized the LLO 
precursor, the olygosaccharyltransferase (OST) complex is responsible for its transferring en 
bloc to the protein in the ER91.  
N-glycosylation in Plasmodium was a controversial issue during the final decade of 
last century since different studies showed diverging results. Dieckmann et al. showed that 
P. falciparum asexual blood stages had little or no capacity of producing N-glycans122. 
Kimura et al. described that N-glycans represented approximately 70% of carbohydrate 
during blood stages123, whereas Gowda et al. stated that P. falciparum had N-linked 
carbohydrates but its presence was minor in relation with GPI-anchor structures103. The 
availability of P. falciparum genome39 enabled the identification of genes involved in the N-
glycosylation pathway in the parasite. Bioinformatic analysis showed that Apicomplexans 
lack some of the Alg genes, the glycosyltransferases responsible for N-glycan synthesis. P. 
falciparum genome has conserved genes encoding for Alg7, Alg13 and Alg14 as well as 
Stt3, the catalytic subunit of the OST complex responsible for the transfer of the N-glycan 
precursor to the protein sequon (Figure 14)99,105,124. In 2010 Bushkin et al.104 showed indirect 




Figure 14. N-glycan precursor in P. falciparum and other apicomplexan parasites. P. falciparum genome lacks Alg enzymes 
adding Man and Glc to the N-glycan LLO precursors. The precursor is predicted to contain just two GlcNAc sugars (GlcNAc2). 
Reproduced from Bushkin et al., Eukaryotic cell, 2010104. 
In higher eukaryotes, protein N–glycosylation plays a crucial role in protein quality 
control, since this glycosylation is important for protein folding125,126. It is also important for 
protein stability, solubility and could be relevant for antigenicity and the antibody 
recognition of modified glycoproteins. However, N-glycans have not yet been completely 
described in Plasmodium species. The biological significance of the short length of N-
glycans in P. falciparum has not been elucidated yet. It may be important to ascertain 
whether this short saccharide chains trigger a specific immune response in the human host, 
since these glycans are not expected to be present in the human glycome99. 
3.3.3. C-mannosylation 
C-mannosylation consists in the addition of a Man residue into tryptophan amino 
acid residues. The precursor of this reaction is a Dol-P-Man, synthesized from GDP-Man. 
The C-1 atom of a single mannose residue is linked to C-2 atom of the indole group of a 
tryptophan (W) amino acid. This is a C-C bond, different from the C-O or C-N bonds 
common in O- or N-glycosylations, respectively. The consensus sequence of the acceptor 
peptide was first defined as WXXW, where the first W residue is C-mannosylated127. 
However, later studies established that the consensus sequence was WXXWXXWXXC 
(where C corresponds with cysteine) and all the tryptophans could be glycosylated128. This 
glycosylation is usually found in proteins containing TSR domains129–131. Several proteins in 
Plasmodium have this domain and the modification has been recently demonstrated102. The 
enzyme responsible for this reaction is DPY19 a mannosyltransferase recently identified in 
Caenhorabditis elegans129 and mammals130. A homolog of this gene can be found in all 
Plasmodius spp. genomes99. The biological significance of this posttranslational modification 
remains to be investigated. 
3.3.4. O-glycosylation 
O–linked glycosylation consists in the covalent link of a sugar to the hydroxyl (OH) 
group of Ser or Thr residues by an O-glycosidic bond. In higher eukaryotes the most 
abundant O-glycosylation type is initiated with the attachment of a GalNAc residue to the 
protein, that can be further extended generating glycoconjugates called mucins91. 
Nevertheless, other types of O-glycosylation also take place in eukaryotic cells, including 




Despite some controversial studies, O-glycosylation had never been clearly 
described in P. falciparum (besides O-fucosylation, see below). The first reports on P. 
falciparum O-glycosylation described the presence of O-glycosylated proteins in P. 
falciparum bloodstages132. After this, Dieckmann-Schuppert et al.133 published an article 
describing the synthesis of O-GlcNAc by malaria parasites. However, the parasite seems to 
lack O-GalNAc glycans (mucin type-like)133. This is also supported by in silico studies 
indicating the absence of a GalNAc transferase activity in Plasmodium 134. More recent works 
from Perez-Cervera et al.135 showed that P. falciparum, as well as Toxoplasma gondii, had 
O-GlcNAcylated proteins. The authors were able to identify T. gondii O-GlcNAc transferase, 
but did not find it in P. falciparum135.  
 O-fucosylation 
The conservation of homolog genes for the GDP-Fuc de novo biosynthetic pathway 
in P. falciparum (i.e GMD and FS, Figure 11) suggests the presence of fucosylated glycans in 
the parasite. The O-fucosylation modification consists in the linkage of a Fuc from a GDP-
Fuc donor to a OH group of a Ser or Thr residue. O-fucosylation is found on Epidermal 
Growth Factor (EGF) and/or on TSR domains in other organisms (Figure 15). Both EGF and 
TSR domains are O-fucosylated by PoFUT enzymes. These enzymes are able to differentiate 
and modify completely folded structures, suggesting that they are related with in protein 
folding quality control 136. EGF O-fucosylation is mediated by PoFUT1, an enzyme that 
localizes in the ER 137. This post-translational modification can be extended with 2 or 3 
monosaccharide residues in mammals and other organisms and plays an important role in 
development138. PoFUT2 is the enzyme responsible for the O-fucosylation of TSR domains. 
It can also be extended with a glucose residue136 
  
 
Figure 15. Two distinct O-fucosylation pathways. 
EGF repeats and TSRs are O-fucosylated by PoFUT1 
and PoFUT2, respectively. Adapted from 
Vasudevan et al., Glycoconjugate Journal, 2014136. 
 
 
Plasmodium species contain several TSR domain-containing proteins, that are 
putative acceptors of PoFUT2-mediated O-glycosylation. TSR domains are small (~60 aa 
residues) cysteine rich motifs with 3 conserved disulfide bonds (Figure 16). They were first 
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described in the multi-domain extracellular matrix protein thrombospondin 1139. In higher 
eukaryotes, these domains have different important functions such as the regulation of 
extracellular matrix organization and of cell-cell interactions140. In 2002 the crystal structure 
of the TSR domain was described, showing that they are folded as three antiparallel strands: 
the strand A is irregular, while strands B and C have β-sheet structure141 (Figure 16). There 
are two main groups of TSR containing proteins depending on the distribution of the 
disulfide bonds. The first group has the top bond linking the third and the fourth cysteine 
(numbered according the order of cysteine appearance in the motifs, as proposed by 
Huwiler et al.142), so the connectivity is C1-C5, C2-C6, C3-C4. The top bond in the second 
group is between cysteine 1 and cysteine 4, so the connectivity between disulfide bonds is 
C1-C4, C2-C5, C3-C6142 (Figure 16B). These domains are conserved in evolution and can be 
found in different organisms, including humans, Plasmodium parasites, Drosophila, C. 
elegans, etc. 
 
Figure 16. TSR domain and scheme of TSR groups 1 and 2. (A) TSR domain of P. falciparum CSP protein. Dark blue represents 
chain A and, light blue and orange are B and C β-sheet structures. Reproduced from Protein Data Bank. (B) Scheme of TSR 
groups 1 and 2. The prototypical disulfide bond patterns are represented as yellow lines. Adapted from Tan et al., Journal of 
Cell Biology, 2002141. 
TSR-domain O-fucosylation is carried out by PoFUT2143 using GDP-Fuc as a donor 
on CX2(S/T)CX2G144,145 consensus sequences. PoFUT2 is only able to modify properly folded 
TSR domains substrate, suggesting the ability to distinguish between folded and unfolded 
structures143. In vitro assays have shown a decrease in secretion of ADAMTS13, a target 
protein of PoFUT2, after silencing PoFUT2 or reducing cellular GDP-Fuc levels145,146. 
Furthermore, PoFUT2 knockout (KO) mice show embryonic lethality147. The crystallization of 
PoFUT2 has recently helped to define in depth aspects about the proteins substrate 
recognition, specificity and catalytic activity148,149. The O-Fuc residues on TSR domains can 
be further elongated by the addition of a Glc residue. The enzyme responsible of this 
glucosylation is a β-1,3 Glucosyltransferase101. In higher eukaryotes, mutations on this 
enzyme lead to the Peter Plus Syndrome, a congenital disorder of glycosylation 
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characterized by eye anterior chamber defects, disproportionate short stature and 
developmental delay among other symptoms101. 
TSR domains are present in different Plasmodium proteins expressed along the life 
cycle of the parasite, being putative acceptors of O-fucosylation modifications. Among 
these, the proteins more studied are MTRAP, CTRP, CSP and TRAP, of which a brief 
description is included below. Other parasite proteins with functions less well known, such 
as SPATR, TRAMP, TREP or TLP, also contain TSR domains. 
• Merozoite TRAP (MTRAP) (PF3D7_1028700)  
MTRAP is a protein from the TRAP family, a surface associated family protein 
conserved across Apicomplexans and related with gliding motility150, a substrate-dependent 
locomotion mechanism. MTRAP is a micronemal protein expressed in Plasmodium blood 
sexual and asexual stages with a cytoplasmic tail that binds to aldolase in vitro. It is released 
and processed during erythrocyte invasion151. The initial failure to knock out MTRAP 
suggested that this protein played an essential role in asexual blood stages parasite 
development 151. Surprisingly, a very recent study showed that MTRAP could be disrupted 
in asexual parasites but was essential for gametocyte egress from erythrocytes152. The KO 
mutants generated in the study confirmed that the protein had no effect on asexual parasite 
growth in vitro or in vivo152. MTRAP, unlike other TSR domain containing proteins described 
below, does not conserve the O-fucosylation consensus amino acids (CXX(S/T)CXXG), 
showing a modified sequence CDKWGEWSECKDGRMHRKVLNCPFIKEEQECDVNNEMAED  
• Circumsporozoite and TRAP Related Protein (CTRP) (PF3D7_0315200) 
CTRP gene encodes for a 2114 amino acid protein that contains a transmembrane 
domain, a short cytoplasmic segment, 6 repeats of von Willebrand factor A (vWF-A) 
domains and 7 TSR domains153. It is expressed in Plasmodium ookinetes and localizes in the 
micronemes, being involved in the invasion of the mosquito midgut epithelium84. CTRP KO 
abolished oocyst production, despite the formation of mature ookinetes. The KO cell lines 
were unable to migrate through the mosquito midgut and produce oocysts96. Further 
studies narrowed CTRP domains’ function, suggesting that the essential part of the protein 
were the 6 vWF-A domains. The elimination of these domains lead to the production of a 
non-infectious parasite line, while the disruption of the 7 TSR domain did not seem to 
significantly affect oocyst development 154. The importance of the conservation of these TSR 




• Circumsporozoite Protein (CSP) (PF3D7_0304600) 
CSP is a highly conserved protein among Plasmodium species. Its structure consists 
in a N-terminal region that contains the so-called Region I domain, a central repeat region 
and the C-terminal region that contains a TSR domain and a GPI-anchor signal. The licensed 
RTS,S malaria vaccine is based on a fragment of this protein, containing the repeat region 
and the TSR domain. CSP is first detected in oocysts and then forms a very dense coat in 
the sporozoite surface155. It plays a critical role during mosquito salivary gland invasion but 
also during human hepatocyte invasion156. Coppi et al.157 proposed a model describing CSP 
function during sporozoite migration from oocysts to the host hepatocytes. It was shown 
that CSP has one adhesive conformation, in which the TSR is exposed, and a non-adhesive 
conformation, in which the protein N-terminus masks the TSR domain. TSR exposure occurs 
during sporozoite development in the oocysts and also during hepatocyte invasion. 
Throughout sporozoite migration, from the hemolymph to the mosquito salivary glands 
and from the skin to the liver, the TSR domain is masked, making it less accessible to 
antibodies. Once the sporozoite gets in contact with hepatocytes, a proteolytic cleavage in 
protein’s Region I is the signal for hepatocyte invasion157. CSP is essential for parasite 
development157, and during the preparation of this thesis, the O-fucosylation and further 
glucose elongation of CSP was reported102.  
• Thrompospondine Related Anonymous Protein (TRAP) (PF3D7_1335900) 
TRAP is a critical parasite protein involved in sporozoite invasion and motility. It 
consists of a region with a vWF-A domain, a TSR domain, a transmembrane domain and a 
cytoplasmic tail domain. It localizes in the sporozoite surface and in the micronemes158,159. 
It has been shown that TRAP binds to hepatocytes through the TSR and vWF-A domains160. 
The TSR domain binds to heparin sulfate proteoglycans (HSPG) on the hepatocyte surface, 
whereas vWF-A binds to heparin with a higher affinity than the TSR domain159. TRAP has 
two key roles during the hepatocyte invasion process. Initially, when the parasite gets in 
contact with the host cell, TRAP is released to the anterior surface of the sporozoite being 
able to interact with hepatocyte HSPG. After that, TRAP migrates and translocates its contact 
zone to the posterior end of the sporozoite, driving the parasite inside the hepatocyte 
cytoplasm159,161. Deletion of TRAP, the TSR domain and/or of the vWF-A domain lead to 
different parasite lines with less sporozoite gliding motility, less salivary gland invasion and 
fewer sporozoite infectivity, underlining the importance of this protein162,163. The C-
mannosylation and O-fucosylation of the TSR domain present in TRAP was reported by 
Swearingen et al102. 
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• Other TSR domain – containing proteins 
Other TSR domain-containing proteins are expressed through the life stages of the 
parasite. Among these we can find: SPATR (PF3D7_0212600), TRAMP (PF3D7_1218000), TLP 
(PF3D7_0616500), TREP (PF3D7_1442600) and TRSP (PF3D7_0104000). SPATR is a protein 
expressed along the parasite life cycle that has been described as a target for liver cell-
invasion inhibitory antibodies164. TRAMP is expressed during the blood stages of the parasite 
but its function in RBC invasion remains unknown165, even though a recent study suggests 
its essential role in this process166. TLP, TREP and TRSP are expressed in sporozoite stages. 
TLP has been suggested to play a role in sporozoite migration from the skin to the liver167, 
while TRSP KO parasites showed a deficiency in hepatocyte cell entry168. TREP is related with 
gliding motility and salivary gland infection169, but more in depth studies regarding all these 
proteins need to be done. Among all these proteins the ones that are expressed during the 












HYPOTHESIS AND OBJECTIVES 
Malaria is a global health problem caused by a protozoan parasite of the genus 
Plasmodium transmitted by female Anopheles mosquitoes. Almost half of the world 
population is at risk of infection and Africa is the region where most of the cases and deaths 
occur. Glycobiology is the study of carbohydrate-related processes including its 
metabolism, glycan structures and biological function. Glycans are key players in cell-
adhesion and in host-pathogen interactions. Hence parasite glycobiology may open new 
research lines leading to discovery of new selective parasiticidal drugs or vaccine candidates 
through the identification of parasite novel essential targets. Until recently, GPI-anchors 
were the only glycan structures well described in Plasmodium parasites. However, recent 
studies confirm the presence of truncated N-glycosylated structures and other 
glycosylations in the parasites102,104,170.  
According to the glycans described in other Plasmodium studies, the presence of 
GDP-Fuc was not expected. However, the genes for the GDP-Fuc de novo biosynthetic 
pathway were conserved in P. falciparum genome, as well as in the other Plasmodium 
species sequenced. Moreover, in other protozoan parasites, such as T. brucei, GDP-Fuc was 
described as an essential sugar nucleotide109. Furthermore, Plasmodium also conserves a 
putative protein O-fucosyltransferase 2, an enzyme that is responsible for the addition of 
fucose on TSR domains. These domains are present in key Plasmodium proteins in different 
stages of the parasite. Based in all this information we hypothesize that P. falciparum has 
an active O-fucosylation mechanism. To explore this hypothesis, the detailed objectives of 
this PhD thesis are: 
• To identify and quantify the pools of sugar nucleotides present in P. falciparum 
blood stages. 
• To confirm PfGMD and PfFS enzymatic activity, the responsible enzymes for GDP-
Fuc synthesis. 
• To describe the biological role of PfGMD and PfFS, by creating null mutant parasites 
of these enzymes and studying its phenotype. 
• To determine the function of P. falciparum PoFUT2 by creating a null mutant and 










  Article 1 
“Biosynthesis of GDP-fucose and other sugar nucleotides in the blood stages of 
Plasmodium falciparum” 
Sílvia Sanz, Giulia Bandini, Diego Ospina, Maria Bernabeu, Karina Mariño, Carmen 
Fernández-Becerra, and Luis Izquierdo 






























 Article 2 
“The disruption of GDP-fucose de novo biosynthesis suggests the presence of a novel 
fucose – containing glycoconjugate in Plasmodium asexual blood stages” 
Sílvia Sanz, Borja López-Gutiérrez, Giulia Bandini, Sebastian Damerow, Sabrina Absalon, 
Rhoel R. Dinglasan, John Samuelson and Luis Izquierdo 







































 Unpublished work 
“Plasmodium parasites with a disrupted O-fucosylation machinery are able to complete the 
human and rodent parasite life cycle.” 
Sílvia Sanz, Eleonora Aquilini, Rebecca Tweedell, Garima Verma, Tim Hamerly, Bernadette 
Hritzo, Abhai Tripathi, Marta Machado, Miguel Prudêncio, João Rodrigues, Rhoel R. 
Dinglasan, Luis Izquierdo   




















Plasmodium parasites with a disrupted O-fucosylation machinery are 
able to complete the human and rodent parasite life cycle  
Authors 
Silvia Sanz1,2,3, Eleonora Aquilini4, Rebecca Tweedell2,3, Garima Verma2,3, Tim Hamerly2,3, 
Bernadette Hritzo2, Abhai Tripathi2, Marta Machado4, Miguel Prudêncio4, João Rodrigues4, 
Rhoel Dinglasan2,3,*, Luis Izquierdo1,*.  
Affiliations 
1 ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, 
Barcelona, Spain  
2Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School 
of Public Health, Baltimore, MD, USA  
3The University of Florida Emerging Pathogens Institute, Department of Infectious Diseases & 
Pathology, Gainesville, FL, USA 
4Instituto de Medicina Molecular, Unidade de Malária, Universidade de Lisboa, 1649–028 
Lisboa, Portugal 





Thrombospondin type I repeats (TSR) domains are commonly O-fucosylated by the protein-
O-fucosyltransferase 2 (PoFUT2) and this modification is required for optimal folding and 
secretion of TSR-containing proteins. The human malaria parasite Plasmodium falciparum 
expresses proteins containing TSR domains that play essential roles in mosquito and human 
host invasion processes during the parasite’s blood and transmission stages. A PoFUT2 
homolog is conserved and expressed by P. falciparum and GDP-fucose, the O-fucosylation 
reaction donor, is actively synthesized and incorporated by the parasite in cell free assays. 
The proteomic detection of the O-fucosylation machinery in salivary gland sporozoites, 
toghether with the observed modification of Thrombospondin related anonymous protein 
(TRAP) or Ciscumsporozoite surface protein (CSP), strongly suggests the conservation of a 
PoFUT2 mediated O-fucosylation mechanism in Plasmodium. Here, we have generated a 
PoFUT2 null-mutant in malaria parasites and, by phenotyping the mutant throughout the 
complete life cycle of human and rodent parasites, we show that PoFUT2 disruption does not 
affect the growth of the blood and mosquito stages of the parasite. This suggests that the O-
fucosylation of TSR-domain is not essential for parasitic development under laboratory 
conditions. 
Introduction 
Malaria is one of the most important human parasitic diseases, causing approximately 214 
million new cases and more than 400000 deaths every year1. It is caused by a protozoan 
apicomplexan parasite of the genus Plasmodium, being P. falciparum the deadliest species. 
Malaria symptoms comprise general discomfort, fever and, chills. In more severe cases, 
malaria can cause breathing problems, organ failure, coma and, eventually death2. 
Chemotherapy is the main tool for malaria control, albeit some vaccine candidates are 
currently under evaluation and one of them has already received regulatory approval3,4. 
Parasites are transmitted by female Anopheles mosquitoes. After the bite of an infected 
mosquito, motile sporozoites are injected into the human dermis from where they travel 
through blood vessels to the liver and infect hepatocytes. One week later, the infected 
hepatocyte ruptures and releases merozoites that reach the blood circulation and invade 
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erythrocytes initiating the asexual reproduction cycle that causes the malaria symptoms. A 
small percentage of blood stage parasites become sexually committed cells, the gametocytes 
that are taken up during a mosquito bloodmeal. Once in the mosquito midgut, gametocytes 
turn into gametes, fertilization takes place and zygotes are formed. These zygotes develop 
into motile ookinetes that traverse the mosquito midgut wall to form oocysts. Every oocyst 
carries more than 10000 sporozoites that invade the mosquito salivary glands and are ready 
to infect another human host5. 
Thrombospondin type 1 repeat (TSR) domains are small (50-60 amino acid residues) cysteine-
knot motifs with 3 conserved disulfide bonds that play important roles in cell adhesion and 
motility6,7. Plasmodium parasites express several TSR domain-containing proteins throughout 
the different stages of their life cycle that are critical for host-cell recognition, motility and 
invasion (Fig. 1)8. These proteins include Circumsporozoite Protein (CSP), Thrombospondin 
Related Anonymous Protein (TRAP), Circumsporozoite and TRAP-related protein (CTRP) and 
Merozoite TRAP (MTRAP) protein and all of them play important roles in sporozoite, ookinete 
and blood stages9-12. Antibodies against these proteins have been shown to inhibit invasion 
and halt parasite life cycle progression13,14. Therefore, they are important vaccine targets15. 
Indeed, the RTS,S licensed malaria vaccine is based in CSP, a GPI-anchored sporozoite protein 




Figure 1. Schematic representation of Plasmodium proteins containing TSR domains. Red boxes represent secretion signals and 
purple boxes represent TSR domains. Predicted transmembrane domains are shown as green boxes and the GPI anchoring signal 
as a blue box. SPATR, Secreted Protein with Altered Thrombospondin Repeat Domain; MTRAP, Merozoite TRAP; TRAMP, 
Thrombospondin-Related Apical Membrane Protein; CTRP,  Circumsporozoite and TRAP Related Protein; TRAP, Thrombospondin-
Related Anonymous Protein; CSP, Circumsporozoite Protein; TLP, TRAP Like Protein; TREP, TRAP-like protein;  TRSP, 
Thrombospondin-Related Sporozoite Protein. Proteins in boldface type (CSP and TRAP) are glycosylated in their TSR domains, 
marked with a red asterisk21. Adapted from Morahan et al., Trends Parasitol, 20098. 
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It has been shown that TSR domains are O-fucosylated by protein O-fucosyltransferase 2 
(PoFUT2)16,17 and the fucose can be further elongated with a glucose residue, generating an 
O-linked disaccharide18. This modification is important for the secretion of TSR-domain 
containing proteins19,20. A recent report demonstrated that CSP and TRAP TSR-domains are 
also O-fucosylated in the sporozoite stages of the malaria parasite21. A homolog of PoFUT2 is 
conserved in all the Plasmodium species sequenced22, and the parasite synthesizes the GDP-
fucose precursor required for O-fucosylation23,24, indicating that PoFUT2 could also mediate 
CSP and TRAP modification in the malaria parasite. Furthermore, this strongly suggests that 
this post-translational modification may be also present in other parasite TSR-containing 
proteins. This prompted us to create PoFUT2 null-mutants in P. falciparum and P. berghei and 
to characterize their phenotypes throughout the blood and transmission stages. In spite of 
the relevance of TSR domain-containing proteins for host-cell invasion and motility, O-
fucosylation is not essential for the survival of the parasite throughout its life cycle. 
Nevertheless, this and other post-translational modifications of malaria vaccine antigens 
could be critical for vaccine design since glycans may alter specific epitopes affecting antibody 
recognition. 
Materials and Methods 
Mice and Ethics statement for animal experimentation 
BALB/c and C57BL/6 mice (6–8 weeks of age) were purchased from Charles River and housed 
in the rodent facility of Instituto de Medicina Molecular (Lisbon, Portugal). All animal 
experiments were approved by the Portuguese official veterinary department for welfare 
licensing and the Instituto de Medicina Molecular Animal Ethics Committee. All animal 
experiments were performed in strict compliance to the guidelines of the institution´s animal 
ethics committee and the Federation of European Laboratory Animal Science Associations 
(FELASA). 
P. falciparum transfection construct 
To disrupt PfPoFUT2 we generated a transfection construct based in the pCC1-plasmid26. 
pCC1-PfPoFUT2 consisted of two fragments of ~850bp and ~960bp, respectively, from 
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different regions of the PfPoFUT2 locus. F1 (nucleotides from -361 to +479 of the PfPoFUT2 
locus) and F2 (nucleotides from 1363 to 630 after of PfPoFUT2 locus) fragments were 
amplified using In-Fusion HD Cloning Kit to SacII/SpeI and NcoI/AvrII restriction sites 
respectively, with the following primers: p3 (CAATGGCCCCTTTCCGCGG 
TCTTATGTCTTATTCTCATTTTGCTT) and p4 (AGATCTTCGGACTAGT 
CTTTTTGTAGCTGCAAGGGGG) for fragment F1 and p5 (ATCGATAACTCCATGG 
TGAGCAATGGATTTGTACAAGGT) and p6 (CAGGCGCCAGCCTAGG TCAAGTGCAAGGGTTCTTTT) 
for fragment F2. The construct generated would integrate into PoFUT2 locus, disrupting it by 
double crossover homologous recombination (Fig. 2A). 
P. falciparum asexual parasite culture and transfection 
P. falciparum NF54 (a kind gift of Teun Bousema, Radboud University Nijmegen Medical 
Centre) parasites were cultured with human B+ erythrocytes (2-4% hematocrit) in RPMI 
medium (Sigma) supplemented with 10% AB+ human serum or 0.5% Albumax II, incubated at 
37ºC in an atmosphere of 92% N2, 3% O2 and 5% CO2 using standard methods42. Human 
erythrocytes and serum were purchased from the Banc de Sang i Teixits (Catalonia, Spain), 
after approval from the Comitè Ètic Investigació Clínica Hospital Clínic de Barcelona. Parasite 
growth was monitored by counting the infected erythrocytes in Giemsa-stained blood smears 
by light microscopy. P. falciparum NF54 parasites were transfected by schizont nucleofection 
as described previously43,44. Briefly, 60 µg of plasmid were transfected using P3 Primary cell 
4D Nucleofector X-Kit (Lonza) program FP158 to 3.3 x 107 Percoll synchronized schizonts. To 
select transfected parasites 2nM of WR99210 were added to the culture 24h after 
transfection. After the appearance of resistant parasites, 2 on/off drug cycling with WR22910 
were started followed by negative selection with 5-Fluorocytosine to select double 
recombinants. Integrant clonal parasites were obtained by limiting dilution. To calculate 
growth curves, tightly synchronized parasites were adjusted to 0.5% and measured by FACS. 






P. berghei cloning, transfection and PCR genotyping 
Transfection experiments were performed on P. berghei ANKA strain 2.34 parasites according 
to the described protocol47. The PoFut2 knockout vector was obtained from the PlasmoGEM 
resource48 with the design number PbGEM-283938 (see http://plasmogem.sanger.ac.uk for 
details of vector design). The final knockout construct was digested with NotI to release the 
fragment for transfection (Fig. 2C). The pyrimethamine-resistant parasite population 
containing the correct genomic integration substituting PoFut2 gene (PbΔPoFUT2) was cloned 
by injecting one parasite per mouse (BALB/c male mice, 6–8 weeks of age). Primers used to 
check the integration of hu-dhfr cassette and conveying resistance to pyrimethamine are p1 
(CATACTAGCCATTTTATGTG), p2 (CTTTGGTGACAGATACTAC), p3 
(AGCACCACGGGGGAAGGACT), p4 (ATGCAAAAACGTCTTCCCTT) and p5 
(TCGAGCAACGATAAAATGCCT). 
P. falciparum southern blotting and PCR analysis 
Genomic DNA (gDNA) was isolated by Phenol/Chloroform method from ∼600 µliters of red 
blood cells (RBC) infected with >5% late trophozoites/schizonts. Two µg of NF54-, SRΔPoFUT2- 
and NF54ΔPoFUT2-gDNA (four different clones) were digested with HindIII and SpeI or NdeI 
in separate reactions and probed with 32P (Perkin Elmer)-labelled F1. PCR with gDNA of NF54, 
SRΔPoFUT2 and NF54ΔPoFUT2 (four different clones) was performed using primers p1 
(TCTTGTACTTCCACCTTGGTGTT) and p2 (CATTCTTCGAAAGGTAAAATAAGAAAA) to detect a 
231bp fragment of the interior of PfPoFUT2 gene. 
P. falciparum gametocyte cultures and mosquito infection 
NF54 and NF54ΔPoFUT2 were diluted to 0.5% mixed stage asexual parasites and 4% 
hematocrit in complete culture medium in six-well plates. The plates were transferred to a 
37°C incubator and cultured using the candle jar method42. The medium was exchanged daily 
from day 1 to day 17, to allow for gametocyte maturation from stage I through stage V. 
Standard membrane feeding assays (SMFA) were performed on day 15-18 post-culture 
initiation. Approximately 60 female An. stephensi or An. gambiae mosquitoes were 
distributed into pint-sized cups and starved of sugar and water for ∼12 hours prior to feeding. 
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P. falciparum NF54 and NF54ΔPoFUT2 gametocyte cultures were pelleted and diluted to 
0.03% or 0.3% gametocytemia with human blood at 50% hematocrit. Blood was washed with 
RPMI media and brought to 50% hematocrit with, heat-inactivated AB serum. Gametocytemic 
blood was kept at 37 °C until feeding. 250 to 300µL of gametocytemic blood were dispensed 
into a water-jacketed membrane feeder at 37 °C, and mosquitoes were allowed to feed for a 
minimum of 45 minutes. After blood feeding, non-blood-fed mosquitoes were removed. 
Blood fed mosquitoes were kept at 26°C, 70% humidity and, 12-hour light:dark cycle. They 
were provided a 10% sucrose solution for energy.  
P. berghei mosquito infections 
An. stephensi mosquitoes were bred at the insectary of the Instituto de Medicina Molecular 
(IMM). For mosquito infection, female BALB/c mice were intraperitoneally injected 
with P. berghei wild type and PbΔPoFUT2 mutant lines. After 3 to 5 days post infection the 
number of exflagellation events were determined with a Zeiss light microscope and a counting 
grid. If >1 exflagellation events per field of view were observed, mice were anaesthetized with 
a mixture of 10% ketamine and 2% xylazin in PBS (100 μL per 20 g mouse body weight i.p.) 
and fed to An. stephensi mosquitoes. Unfed mosquitoes were removed and fed mosquitoes 
were maintained at 19–22 °C and in 50–80 % relative humidity. Mosquitoes were used 10–23 
days post infection for further experiments.  
Oocyst counting and imaging 
For P. falciparum oocyst counting, eight to ten days after the feeding, mosquito midguts were 
dissected and stained with 0.2% mercurochrome in water for 9 minutes. Midguts were placed 
on a slide with a drop of PBS, overlaid with a coverslip, and examined for oocysts counting 
using brightfield microscopy at 200x total magnification.  Each midgut was imaged with 
Progress Capture Pro software to measure oocyst diameter, ensuring oocyst in all planes were 
visible. P. berghei infected midguts were collected and stained with 0.5 % mercurochrome, 
10 days after infection. Oocysts were counted to determine the intensity of infection (number 




Sporozoite purification and counting 
On day 14 post-feeding, 30 mosquitoes, infected with each P. falciparum line (NF54 and 
NF54ΔPoFUT2) were dissected to obtain salivary glands. Each pair of salivary glands was kept 
in 100 µL of PBS in a 1.5 ml tube. The tubes were spun down at 1,200xg, for 3 minutes at room 
temperature. The salivary gland pellet was gently crushed in the 1.5 ml tube and vortexed for 
3 seconds to resuspend the salivary gland contents in PBS. The tubes were spun down again 
at 1,200xg for 3 minutes at room temperature. Sporozoites were counted blindly on a 
hemocytometer by averaging 2 fields. Unpaired t-test was run using GraphPad. P. berghei 
sporozoites (PbWT and PbΔPoFUT2) were collected on 21-24 days post infection from 
infected An. stephensi females bred at Instituto de Medicina Molecular. Salivary glands were 
dissected and kept in non-supplemented RPMI medium at 4ºC. After dissection, salivary 
glands were smashed with a pestle in a microcentrifuge tube. To eliminate mosquito debries 
and isolate the sporozoites, smashed samples were filtered on a 70 µm strainer. Sporozoites 
were then counted in a Neubauer chamber using an Olympus CKX41 inverted microscope. 
P. berghei sporozoite infectivity to mice 
For transmission experiments naïve C57BL/6 mice were exposed to 10 
infected P. berghei wild type or PbΔPoFUT2 mosquitoes for 30 minutes; 3 mice were used per 
parasite clone. Parasitemias were followed daily by counting Giemsa smears from a drop of 
tail blood. Animals were monitored daily for clinical signs of cerebral malaria (CM) (head 
deviation, convulsions, ataxia and paraplegia). 
Results 
Generation of PfPoFUT2 and PbPoFUT2 null mutants 
Several key Plasmodium proteins that play important roles along the different stages of the 
parasite developmental cycle contain TSR domains (Fig. 1). These domains are O-fucosylated 
by the glycosyltransferase PoFUT225, of which a homolog is found in the parasite genome. To 
assess the biological role of PoFUT2 through the parasite life cycle, we knocked out this gene 
in human and rodent malaria parasite species, P. falciparum and P. berghei, respectively. P. 
falciparum PoFUT2 (PfPoFUT2) was disrupted by double crossover recombination using a 
83 
 
targeting construct (pCC1-PfPoFUT2)26 that replaced the gene with a hu-dhfr selection 
cassette (Fig. 2A) in P. falciparum NF54 line, which produces viable gametocytes. A similar 
approach was used to ablate P. berghei PoFUT2 (PbPoFUT2), using PbGEM-283938 plasmid 
(Fig. 2C) kindly provided by PlasmoGEM27. After cloning hu-dhfr resistant parasites by limiting 
dilution, PCR or Southern Blot analyses confirmed PoFUT2 disruption in both Plasmodium 









Figure 2. PoFUT2 transfection constructs and integration events in human and rodent malaria parasites. (A) Scheme of the 
transfection plasmid (pCC1-PfPoFUT2) used to target and disrupt PfPoFUT2 in P.falciparum NF54 parasites (NF54) and the 
expected double crossover recombination event (NF54∆PoFUT2). Black boxes represent upstream and downstream DNA 
sequence flanking the PfPoFUT2 gene locus. Position of HindIII (H), NdeI (N) and SpeI (S), position of F1 probe (thick black line), 
predicted length of the resistance fragment (thick black lines) and position of p1 and p2 primers are shown. (B) Southern blot of 
HindIII+SpeI and NdeI digested genomic DNA from NF54, SRΔPoFUT2 and NF54ΔPoFUT2 parasite clones. SR refers to Single 
recombinant parasites before negative selection with 5-Fluorocytosine.  Hybridisation of F1 probe to digested DNA from 
NF54ΔPoFUT2 clones revealed restriction fragment sizes consistent with the replacement of a fragment of PfPoFUT2 by 
integration of the hu-dhfr drug-resistance cassette (left panel).  PCR using as template genomic DNA of NF54, SRΔPoFUT2 and 
different NF54ΔPoFUT2 clones and primers p1 and p2 (right panel). The absence of a band in NF54ΔPoFUT2 clone lanes reflects 
the replacement of PfPoFUT2. (C) Scheme of the PlasmoGem transfection plasmid (PbGEM-283938) used to disrupt PbPoFUT2 
in P. berghei ANKA parasites and the expected double crossover recombination events (Pb∆PoFUT2). Black boxes represent 
upstream and downstream DNA sequence flanking the PbPoFUT2 gene locus. Position of NotI (N), predicted length of PCR 
fragments (black lines) and position of primers p1, p2, p3, p4 and p5 is shown. TelN refers to Telomerase, RepA to Helicase, cB 
to arabinose inducible origin and KanR to the Kanamycin resistance cassette. attB1 and attB2 are the recombination sequences 
for the Gateway technology. (D) Genotype analysis of P. berghei transfectants (left panel) and P. berghei clones (right panel). 
PCRs on the genomic DNAs of PbANKA wt and PbΔPoFUT2 clones were done using primers p5 and p1, p3 and p4 and p4 and p2 
for integration, wild type locus and cassette presence respectively. The presence of the integration band and the absence of the 
wt locus band in PbΔPoFUT2 parasites reflect that the replacement of the gene has taken place. 
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PoFUT2 null mutants do not show significant growth defects in P. falciparum or P. berghei 
asexual blood stages 
PoFUT2 ablation demonstrates that the gene is not required for growth in the asexual blood 
stages of the parasite in culture or in a rodent model of infection. It has been suggested that 
proteins with TSR domains expressed in the Plasmodium asexual blood stages, such as 
the thrombospondin-related apical merozoite protein (TRAMP)28,29, are involved in host cell 
invasion8. Thus, PoFUT2 absence might alter the secretion or function of these proteins 
affecting parasite’s growth. Nevertheless, NF54ΔPoFUT2 knock out parasites exhibited 
growth rates similar to those of NF54 wild type strains (Fig. 3). Furthermore, the disruption of 
PbPoFUT2 in P. berghei ANKA strain (PBANKA_0810400) also confirmed the non-essentiality 




PoFUT2 null mutant parasites infect mosquitoes and exhibit normal oocyst production 
To test whether PoFUT2 is affecting sexual stage development of malaria parasites, An. 
gambiae and/or An. stephensi mosquitoes were blood fed on gametocytemic human blood 
or on mice infected with wild type or PoFUT2 null mutant parasites. We did not observe 
significant differences in the parasite’s ability to generate gametocytes (data not shown) and 
Figure 3. P. falciparum blood stages do not show any significant difference. (A) Synchronous ring stage NF54 (white) and 
NF54ΔPoFUT2 (grey) growth was monitored over two complete life cycles (96h) by flow cytometry using SYTO 11 as previously 
described (left panel). Growth rate of NF54 (white) and NF54∆PoFUT2 (grey) is represented (right panel) 
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to infect mosquitoes, suggesting that merozoite TRAP (MTRAP) protein, an essential protein 
for gamete egress from the RBC, is not affected by PoFUT2 disruption152.  
Circumsporozoite and TRAP-related protein (CTRP), an ookinete protein containing 7 TSR 
domains, is essential for mosquito infection (Fig. 1)30. Thus, we analyzed infected mosquito 
midguts to assess whether PoFUT2 ablation could alter oocyst development in P. falciparum 
or P. berghei. 8-10 days after blood fed with infected blood, mosquitoes were dissected to 
evaluate the presence of oocyst in midguts. No significant differences were appreciated (Fig. 
4A and 4B), strongly suggesting that the invasion of the midgut epithelium was not affected 
in P. berghei or P. falciparum PoFUT2 mutants. Furthermore, the diameter and mean size of 
P. falciparum oocysts was similar in wild type and mutant parasites (Supplementary Fig. S1). 








Figure 4. Oocyst production is similar in wild type and mutant parasite lines in both Plasmodium specie. (A) 30 An. gambiae 
female mosquitoes were fed at 0,03% gametocytemia. NF54 (white) and NF54∆ PoFUT2 (grey) oocyst number per midgut were 
counted 8 to 10 days post blood feed. Mean of the oocyst per midgut of wild type and mutant is represented. Two representative 
experiments are showed. Statistical analysis (unpaired t-test, 95% CI) did not show any significant difference (p value: 0,7609 and 
0,4262 respectively)  (B) 10 An. stephensi female mosquitoes were fed on BALB/c mice. PbWT (white) and PbΔPoFUT2 (grey) 
oocyst number per midgut were counted 10 days post blood feed. Mean of the oocyst per midgut of wild type and mutant is 
represented. Two representative experiments are showed. Statistical analysis (unpaired t-test, 95% CI) did not show any 
significant difference (p value: 0.2026 and 0.4553 respectively). 
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PoFUT2 null mutant sporozoites are able to colonize Anopheles salivary glands and to re-infect 
mice 
We also analyzed the number of sporozoites per pair of salivary glands after mosquito 
infection. Anopheles mosquitoes carrying mutant or wild type parasites showed similar 
numbers of salivary glands sporozoites in both P. falciparum and P. berghei species (Fig. 5A 
and 5B). Thus, salivary gland infection takes place normally in the absence of PoFUT2. 
Remarkably, P. berghei PoFUT2 null mutant sporozoites were able to infect C57BL/6 mice by 
direct bite-back (Fig. 5C). This result showed that PbPoFUT2 mutants are fully infectious and 
able to go through hepatocyte infection and liver stage development. This was also confirmed 
by in vitro hepatic infection and cell traversal activity experiments performed using P. berghei 
PoFUT2 mutant parasites (Supplementary Fig. S2A and B). Interestingly CSP, the major 
sporozoite surface protein, was present in the sporozoite surface of P. falciparum parasites 
upon PoFUT2 deletion, suggesting that CSP secretion is not significantly altered in absence of 













O-fucosylation, the process of adding a fucose residue to the -OH side chains of serines or 
threonines in TSR cysteine-rich domains25,31, is mediated by PoFUT2 O-fucosyltransferase32. 
The O-fucosylation of P. falciparum CSP and TRAP sporozoite proteins has been recently 
demonstrated21. Considering the relevance of these and other TSR domain-containing 
proteins for Plasmodium invasion and motility8, we created a PoFUT2 null-mutant in human 
and rodent parasites to completely assess the effect of PoFUT2 disruption throughout the 
parasite life cycle. The isolation of PoFUT2 null mutants both in P. falciparum and P. berghei 
species revealed that the protein is not necessary for parasite development. The ability of null 
mutants to complete the entire passage through the mosquito and to infect hepatocytes, 
suggests that the absence of PoFUT2 does not affect the function of key TSR-containing 
proteins such as CTRP, TRAP or CSP. Interestingly, a recent genome-wide screen performed 
in Toxoplasma gondii parasites showed that PoFUT2 was not among the genes conferring a 
more significant fitness cost to parasite tachyzoites during human fibroblast infection33. 
Therefore, O-fucosylation of TSR-domains seems to be dispensable for parasite growth under 
laboratory conditions.  
Besides mediating important interactions between pathogens and their hosts34, glycans are 
also involved in protein folding and secretion35,36. PoFUT2 endoplasmic reticulum (ER) 
Figure 5. Sporozoites per salivary gland numbers are comparable between wild type and null mutant parasites. (A) NF54 
(white) and NF54∆ PoFUT2 (grey) sporozoites per mosquito were counted 14 days post blood feed. Mean and Standard Error of 
Mean (SEM) of sporozites per mosquito is represented. Three representative experiments are shown. Statistical analysis 
(unpaired t-test, 95% CI) showed no significant difference (p value 0,8705; 0,3154 and 0,2862 respectively) between NF54 and 
NF54ΔPoFUT. (B) 21-24 days post infection PbWT (white) and PbΔPoFUT2 sporozoites were dissected, pooled and counted using 
hemocytometer. Number of sporozoites per mosquito of three independent experiments is represented. (C) Comparision of mice 
survival bitten by 10 PbWT or PbΔPoFUT2 infected mosquitoes. Animals were monitored daily for clinical signs of cerebral malaria 
(CM) (head deviation, convulsions, ataxia and paraplegia) and all of them developed CM around the same time. No significant 
differences were observed between the two groups (left panel). Scheme of PbWT PoFUT2 locus and PbΔPoFUT2 deleted locus 
and genotype analysis of P. berghei parasites after the mouse bite-back (right panel, top). PCRs on the genomic DNAs of PbANKA 
wt and PbΔPoFUT2 after bite back were done using primers p5 and p1  and p3 and p4 for integration and wild type locus presence. 
The presence of the integration band and the absence of the wt locus band in the PbΔPoFUT2 parasites reflect that PoFUT2 
disruption was maintained in mutant parasites after bite back infection (right panel, bottom). 
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localization, its ability to distinguish between folded and unfolded structures and its 
importance for protein secretion, indicates that this glycosyltransferase plays a role in the 
folding, quality control and efficient secretion of TSR-contaning proteins19,25. Thus, PoFUT2-
mediated TSR domain O-fucosylation may be contributing to adequate protein secretion 
under specific conditions, such as those that generate ER-stress37, as it is the case of other ER-
residing chaperones and glycosyltransferases38. Further experiments should help to ascertain 
the significance of O-fucosylation for the adequate secretion of critical TSR domain-containing 
proteins under ER-stress conditions, in a parasite particularly sensitive to this pressure39. 
CSP is the main immunodominant protein antigen in the sporozoite surface. This protein 
contains a glycosylated21 C-terminal TSR-domain and it is essential for the sporozoite journey 
from mosquito midgut to the vertebrate host hepatocyte target10. The licensed RTS,S malaria 
vaccine is based in a fragment of CSP, containing part of the protein sequence repeats, the 
region III and the TSR domain. In the vertebrate host, CSP region I is cleaved, unmasking the 
TSR domain and exposing it to the host circulatory system10. Several studies emphasize the 
importance of knowing the structure of vaccine candidates due to its potential impact in 
antibody recognition40,41. Thus, the glycosylation of CSP and other key parasite antigens, may 
be important for the generation of an effective immune response against the parasite. The 
confirmation that Plasmodium PoFUT2 is involved in TSR-domain O-fucosylation may pave 
the way for the in vitro production of glycosylated antigens inducing more specific and 
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Fig S1. P. falciparum NF54 and NF54ΔPoFUT2 oocysts are similar in size. (A) A. gambiae female mosquitoes were fed at 0,03% 
gametocytemia and oocysts were visualized by mercurochrome staining of mosquito midguts 8-10 days after mosquito feeding. 
(B) The range of oocyst diameter (μm) (left panel) and the mean size (μm) (right panel) of the NF54 (white) and NF54∆PoFUT2 
(grey) oocyst is represented. Statistical analysis (unpaired t-test, 95% CI) showed that oocysts are not significantly different 
(pvalue 0,6897). 
Fig. S2. Characterization of PbWT and PbΔPoFUT2 sporozoites. (A) In vitro hepatic infection was performed and percentage of 
infected cells normalized to wild type is represented. Statistical analysis (Mann Whitney test) did not present any significant 
difference (p value: 0,1716) (left panel). Area of exoerythrocytic forms (EEF) was measured and statistical analysis (unpaired t-
test, 95% CI) did not show any significant difference. (p value: 0,3931) (right panel). (B) Cell traversal activity was measured using 
Huh7 cells and percentage of traversed cells is represented. Statistical analysis (Mann Whitney test) show that  traversal activity 








Supplementary materials and methods 
Midgut immunofluorescence assay  
An. stephensi midguts were dissected 12 days post-infection and fixed in 4% 
paraformaldehyde for one hour on ice or overnight at 4°C. Midguts were incubated with 3% 
Bovine Serum Albumin (BSA) and 0.1% Triton-X-100 to block and permeabilize for one hour 
at room temperature or overnight at 4°C. Samples were washed in 1X Phosphate Buffered 
Saline (PBS) and incubated overnight at 4°C in a 1:1000 dilution of 0.5 mg/ml 2A10 mouse 
anti-PfCSP, in 3% BSA. Following incubation with the primary antibody, midguts were washed 
in 1X PBS and incubated for one hour with a 1:1000 dilution of the 2 mg/ml Alexa Fluor goat 
anti-mouse 594 antibody in 3% BSA while being protected from light. After secondary 
antibody incubation, midguts were washed in 1X PBS, deposited on a slide in a drop of 
ProLong diamond Antifade Reagent with DAPI, and covered with a 22x22 mm coverslip. Slides 
were viewed and imaged using a Nikon Upright E800 and images were edited using the GNU 
Image Manipulation Program (GIMP). 
Fig. S3. CSP protein is present in the wild type and mutant parasites even upon PfPoFUT2 deletion. An. gambiae midguts 
infected with NF54 and NF54ΔPoFUT2 were dissected 8-10 days after blood feed and probed with anti-PfCSP antibodies and an 
Alexa, stained with DAPI, and imaged at 10X.  Presence of CSP revelead that the secretion of the protein is not  altered in the 
absence of  PfPoFUT. 
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Human hepatoma cell culture, cell traversal activity an in vitro infection 
Huh7 cells, a human hepatoma cell line, were cultured in RPMI 1640 medium supplemented 
with 10% v/v FBS, 0.1 mM non-essential amino acids, 50 µg/ml penicillin/streptomycin, 2 mM 
glutamine and 1 mM HEPES (final concentrations), pH 7 and maintained at 37°C with 5% CO2 
The traversing activity of the sporozoite was examined using a standard cell-wounding and 
membrane repair assay49. Huh7 cells (1.0x104 per well) were seeded in 96-well plates the day 
before infection. Sporozoites were added to cells for 2 h in the presence of 0.5 mg/ml FITC-
labeled dextran. Cells were collected for flow cytometry analysis at 48 hours post infection 
(hpi) and analyzed on a BD LSR Fortessa flow cytometer with the DIVA software (version 6.2). 
Analysis was carried out using the FlowJo software (version 6.4.7, FlowJo). 
For in vitro hepatic infections, cells were seeded on glass coverslips in 24 well plates the day 
before infection. Sporozoite addition was followed by centrifugation at 1800xg for 5 min. 48 
hpi, cells were fixed for 20 min at RT and incubated with permeabilization/blocking solution 
(0.1% v/v Triton X-100, 1% w/v BSA in 1x PBS) for 30 min at room temperature. Parasites were 
stained with an anti-UIS4 antibody (dilution 1:1000) for 1 h at room temperature, washed 
three times and further incubated with anti-mouse AlexaFluor 488 secondary antibody (1:400 
dilution) in presence of Hoeschst (1:1000 dilution) for nuclear staining. Coverslips were 
mounted on microscope slides with Fluoromount (SouthernBiotech). Widefield images for 
size determination were acquired in a Zeiss Axiovert 200M microscope. Images were 
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Malaria is one of the major global health problems affecting humans in developing 
countries. Important progresses towards malaria control and elimination have been 
achieved in the last decade, but much more efforts are needed to advance towards the 
goal of malaria eradication6. Despite the recent approval and recommendation of the RTS,S 
vaccine171, chemotherapy is still the main strategy for malaria treatment. Unfortunately, the 
emergence of drug resistances threatens malaria control and elimination goals. Therefore, 
more research is urgently needed to complete our biochemical and cellular Plasmodium 
knowledge with the aim to describe novel parasite mechanisms amenable for intervention. 
Glycobiology is the study of carbohydrate and glycoconjugate related processes. Glycans 
are often related with host-pathogen interactions and cell-cell adhesion and 
communication mechanisms. Describing the glycobiology of Plasmodium and its relevance 
for the parasite life cycle (through all the different stages) may open new avenues for the 
identification of new vaccine and/or drug candidate targets. 
Sugar nucleotides in P. falciparum 
Previous Plasmodium glycobiology works hadn’t elucidated the presence of fucose 
in the malaria parasite97,103,104,172,173. In this thesis, I describe the synthesis of GDP-Fuc and 
other sugar nucleotides in P. falciparum, shedding more light into the relevance of these 
precursors in the parasite. Thus, my first job reported evidence of the presence of different 
sugar nucleotides in the blood stages of P. falciparum174, including GDP-Fuc (Figure 17). 
These findings improved the description of the metabolic pathways involved in the synthesis 




Figure 17. Sugar nucleotide biosynthetic pathways identified in the genome of P. falciparum. Predicted known fates of sugar 
nucleotide donors according to the glycoconjugates described in P. falciparum are in italics (or marked with a question mark 
if the fate is unknown). Activated sugars, used for glycoconjugate biosynthesis are boxed. Dotted lines indicate confirmed 
salvage pathways and sugars, take up from the medium, are underlined. GNA is represented with a discontinue black arrow 
because it can not be identified in the parasite genome The suggested pathway for the biosynthesis of UDP-Gal through the 
activity of the UDP-sugar pyrophosphorylase enzyme is indicated with a grey discontinuous arrow. Abbreviations: HK, 
hexokinase; G6PI, glucose 6-phosphate isomerase; GFPT, glucosamine-fructose-6-phosphate aminotransferase; GNA, 
glucosamine-phosphate N-acetyltransferase; PAGM, phosphoacetylglucosamine mutase; UAP, UDP-N-acetylglucosamine 
pyrophosphorylase; MPI, mannose-1-phosphate isomerase; PMM, phosphomannomutase; MPG, mannose-1-phosphate 
guanyltransferase; DPM1, Dolichol-phosphate-mannosyltransferase polypeptide 1; GMD, GDP-mannose 4,6-dehydratase; FS, 
GDP-L-fucose synthase; PGM, phosphoglucomutase; UGP, UTP-glucose-1-phosphate uridylyltransferase; USP, UDP-sugar 
pyrophosphorylase; GALE, UDP-glucose 4-epimerase; GK, galactokinase.  
In this regard, the identification of UDP-Gal in the asexual blood stages of P. 
falciparum did not correlate with the apparent lack of an enzymatic activity responsible for 
the synthesis of this sugar nucleotide (Figure 17). UDP-Glc 4-epimerase (GALE)175, involved 
in the synthesis of UDP-Gal through the epimerization of UDP-Glc, which is present in many 
organisms, including T. brucei and in T. cruzi, cannot be identified in Plasmodium 
genomes99. A homolog of UTP-glucose 1-phosphate uridyltransferase (UGP) 
(PF3D7_0517500) is annotated in P. falciparum genome. Other organisms, such as the 
protozoan parasite Leishmania major, present a similar activity, UDP-sugar 
pyrophosphorylase (USP) enzyme176 with a broader substrate range than UGP. USP can use 
Gal-1P, Glc-1P or other sugars (i.e. D-xylopyranose-1P, UDP-β-L-arabinopyranose, or UDP-
α-D-galacturonate)177,178. Thus, a possible way of UDP-Gal synthesis in P. falciparum would 
be through PF3D7_0517500, that shows significant similarities to USP enzymes. Further 
works are currently being performed to characterize this enzymatic activity (Cova et al. in 
preparation). 
UDP-galactose:β-galactoside-α1-3-galactosyltransferase (α1,3GT) was inactivated 
in humans 28 milion years ago, possibly as a result from a selective pressure exerted by a 
pathogen179. This enabled the generation of a strong immune reactivity against these α-
galactose (α-gal) epitopes179.  The fate of the UDP-Gal pool in P. falciparum species is not 
known, but some studies suggested the presence of α-galactosylations in the blood stages 
of the parasite. These works also showed higher titers of anti-α-gal antibodies in sera from 
patients in malaria endemic areas180,181. However, later studies did not manage to identify 
α-gal-containing glycans in the asexual blood stages of the parasite182,183. Nevertheless, 
Yilmaz et al. recently reported indirect evidence of the presence of an α-gal containing 
glycan in the surface of Plasmodium sporozoites from different species, by the binding of 
an α-gal specific lectin (i.e. Bandeiraea (Griffonia) simplicfolia-1 isolectin IB4). The authors 
also showed that the immune response against these glycans conferred malaria immune 
protection, associated with anti-α-gal antibodies170. The presence of a UDP-Gal pool in the 
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parasite suggests that this precursor may contribute to the biosynthesis of gal-containing 
glycans, despite an α-galactosyltransferase has not been described in the parasite genome. 
Our data also demonstrated the expected presence of UDP-GlcNAc in the blood 
stages of the parasite174. There are two main metabolic routes described for the synthesis 
of UDP-GlcNAc: via a de novo pathway from Fru-6P or via a salvage pathway using a 
hexokinase, usually fed by GlcN. However, both routes require a glucosamine-6-phosphate 
N-acetyltransferase (GNA) activity (Figure 17), an enzyme that cannot be identified in 
Plasmodium genome, although it has been completely characterized in other eukaryotes, 
such as S. cerevisae184, T. brucei185, Aspergillus fumigatus186 and many others. The presence 
of an active aminosugar pathway indicates that a GNA activity is also present in P. 
falciparum107,108. UDP-GlcNAc feeds the GPI-anchor biosynthesis, and it is also required for 
N-glycan synthesis in Plasmodium104. Therefore, the biosynthesis of this sugar nucleotide is 
an important process in the parasite, since these glycosylations are possibly critical for 
parasite survival and infectivity114. Our lab is currently working to elucidate the activity of 
Plasmodium GNA as well as in other apicomplexan parasites (Cova et al., in preparation). 
GDP-Fuc in P. falciparum 
P. falciparum genome encodes for homolog genes of the GDP-Fuc de novo 
biosynthetic pathway:  GMD (GDP–mannose 4,6–dehydratase) and FS (GDP– L– fucose 
synthase) (Figure 17). It also lacks homolog genes for the fucose salvage pathway, consistent 
with the inability of the parasite for taking up [3H]-Fuc from the media174. The finding of a 
GDP-Fuc pool in the asexual stage parasites agreed with the maintenance of GMD and FS 
genes and the demonstration of their enzymatic activity in vitro. Both enzymes localize in 
the cytoplasm and are expressed, at relative low levels, along the intraerythrocytic asexual 
life cycle of the parasite. The incorporation of [3H]-GDP-Fuc by parasite extracts in cell-free 
assays suggested the presence of fucosyltransferase activities and of fucosylated conjugates 
in the blood stages. The presence of this putative fucosylation was indirectly proved in my 
next work187. The targeted disruption of GMD, responsible for GDP-Fuc synthesis, reduced 
Ulex europaeus agglutinin I (UEA-I) fucose-specific binding in the parasite surface. However, 
surprisingly, GMD disruption did not seem to significantly affect to the levels of GDP-Fuc 
present in the cell. This suggested the existence of an alternative route for the generation 
of this sugar nucleotide pool by the parasite, although we were not able to demonstrate a 
specific incorporation of [3H]-Fuc or [3H]-GDP-Fuc in mutants. Different studies have 
described passive transportation of monosaccharides, aminoacids and other molecules in 
P. falciparum188,189, thus the parasite might be using equillibrative transportation 
mechanisms to obtain GDP-Fuc from the GDP-Fuc pools present in the RBC. Nevertheless, 
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even though the GDP-Fuc pools in the null mutant parasites were comparable with parental 
wild type parasites, GMD disrupted parasites showed the aforementioned clear decrease of 
UEA-I binding. Therefore, although the GDP-Fuc de novo biosynthetic pathway may not be 
the only source of this sugar nucleotide, its disruption seems to be shutting down the 
synthesis of a fucosylated glycoconjugate, without any other obvious fitness cost for the 
parasite.  
Fucose metabolism is essential in other protozoan parasites, such as T. brucei. A 
conditional mutant of TbGMD showed a decrease in GDP-Fuc, indicating that the de novo 
pathway was the only source of GDP-Fuc in this organism. Mutants went through growth 
arrest in both life cycle stages (bloodstream and procyclic forms), but the authors were 
unable to identify any Fuc-containing glycans present in T. brucei109. T. gondii, as T. brucei, 
does not have a GDP-Fuc salvage pathway using the de novo biosynthetic route to generate 
GDP-Fuc. In a recent paper, Bandini et al. suggested that this pathway may be essential or 
very deleterious for the parasite. The authors were capable of showing a binding of Aleuria 
aurantia lectin (AAL, a fucose specific lectin) in punctuate structures in the nuclei, close to 
the nuclear pore complex190. Nevertheless, in P. falciparum GDP-Fuc de novo metabolism is 
not essential for the asexual blood stages of the parasite187. However, GMD and/or FS may 
be important for other stages of the parasite. Both enzymes are detected in proteomic 
studies performed with P. falciparum sporozoites191. 
The presumed presence of a fucosylated glycoconjugate in the surface of P. 
falciparum parasites would require the action of a fucosyltransferase187. However, the only 
fucosyltransferase candidate identified in the parasite genome is PoFUT2 (PF3D7_0909200), 
which shows gene expression in the mature stages of the intraerythrocytic asexual parasite 
cycle174.Proteomic analyses of highly purified salivary gland sporozoites from P. falciparum 
and P. yoelii detected this O-fucosyltransferase191. PoFUT2 is responsible for the O-
fucosylation of TSR motifs, small cysteine-containing domains that have been related with 
several functions such as cell adhesion, the regulation of the extracellular matrix or cell-cell 
communication136,140. Remarkably, several key P. falciparum proteins contain TSR domains161 
and some of these proteins have been associated with motility and host cell invasion, a 
critical process for the parasite survival and propagation. Very recently, the O-fucosylation 
of two of these proteins, CSP and TRAP, has been demonstrated102. Taken together, this 
strongly suggests the conservation of an O-fucosylation mechanism in the parasite. In order 
to assess its relevance, we decided to generate a PoFUT2 KO and study its phenotype. The 
viability of P. falciparum and P. berghei blood stage PoFUT2 mutants revealed that the O-
fucosylation machinery is not essential for parasite development. Furthermore, PoFUT2 KO 
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capacity to complete the entire parasite life cycle through the mosquito stages and to infect 
hepatocytes, clearly indicates that the lack of PoFUT2 is not significantly affecting key roles 
of TSR domain-containing proteins. In order to confirm the function of PoFUT2 in the 
parasite, we are currently assessing the glycosylation state of known fucosylated proteins, 
such as CSP or TRAP, by targeted proteomic approaches in mutant cell lines. This will further 
confirm whether PoFUT2 is the responsible for this posttranslational modification. 
PoFUT2 in protein folding and quality control 
Glycans do not only play important roles in cell-cell interaction and communication 
but are also involved in protein folding and quality control processes192. In higher eukaryotes 
N-glycans are recognized by ER chaperones that assist in the proper folding of the nascent 
proteins91. Samuelson et al. and others have described the effects of N-glycans during 
protein quality control in different organisms193. PoFUT1 is another ER localizing O-
fucosyltransferase that differentiates folded and unfolded EGF domains. In different works 
it has been described that PoFUT1 has a chaperone like activity besides the 
fucosyltransferase activity194,195 that contributes to the appropriate folding of EGF-containing 
proteins. Both, the chaperone and the transferase activities are independent196. PoFUT2 and 
O-fucosylation may also be involved in comparable quality control mechanisms in the 
parasite. PoFUT2, which is an ER localizing protein, only fucosylates properly folded TSR 
domains, indicating that, as PoFUT1, it distinguishes between folded and unfolded 
domains143. Moreover, different studies have shown that inhibiting O-fucosylation results in 
protein secretion defects in vitro145 and that the elimination of PoFUT2 in mice produces 
embryonic lethality due to severe defects during the gastrulation process147. These results 
suggest a role of PoFUT2 in quality control folding and secretion of TSR containing 
proteins136. The publication of PoFUT2 crystal structure148 and the aforementioned 
evidences relating PoFUT2 absence with secretion defects agree with a model in which 
PoFUT2 is involved in TSR folding (Figure 18). TSR domain cysteines need to be correctly 
paired for a proper domain folding. An unfolded TSR will be in equilibrium with different 
folding intermediates, with the cysteines paired incorrectly. PoFUT2 will only recognize and 
fucosylate the substrate when cysteines are partially but correctly paired (C1-C5 and C3-C4 
or C1-C5 and C2-C6). This would shift the equilibrium to the fully folded fucosylated TSR 
domain (Figure 18). This model suggests that the fucosyltransferase activity and the 




Figure 18.PoFUT2 role in TSR domain folding. The TSR domain (i) may exist as many different folding intermediates (ii) in 
equilibrium. When cysteines are partially but correctly paired, PoFUT2 recognizes it as a substrate and fucosylates it (iii). This 
drives the folding reaction to the formation of a fully folded TSR domain (iv). Reproduced from Vasudevan et al., Glycoconj. 
J, 2014136. 
Unlike what has been described in other cell types or organisms147,197, deletion of 
Plasmodium PoFUT2 appears to not affect significantly the folding and/or secretion of 
Plasmodium TSR domain-containing proteins in standard laboratory conditions, judging by 
the ability of the parasite to complete its life cycle. However, O-fucosylation may still be 
important for protein quality control when the parasites are under different ER stress 
conditions136, as it is the case for other glycosyltransferases involved in similar quality control 
processes198,199.  Therefore, more experiments regarding this issue may help to determine 
the role of Plasmodium PoFUT2 during protein folding and quality control. 
O-Fuc on TSR domains can be further elongated with a glucose residue by a β1,3-
glucosyltransferase101. It has been proposed that this enzyme, responsible for the glucose 
elongation in humans, also mediates a quality control mechanism for recognizing, 
modifying and stabilizing properly folded TSR domains93. Deficiency in this enzyme is 
responsible for the human Peter Plus Syndrome, an autosomal recessive disorder 
characterized by eye and developmental defects200. A homolog of this gene is not 
annotated in P. falciparum genome, but BLAST analysis with the human enzyme identified 
a putative parasitic protein with 31% identity and 50% similarity102,201. Previous studies 
indicate that this protein (parasite-infected erythrocyte surface protein 1 or PIESP1; 
(PF3D7_0310400)), is present in the surface of infected RBCs, which is challenging to 
associate with a predicted glucosyltransferase activity201. As mentioned before, it has been 
reported that P. falciparum CSP and TRAP are O-fucosylated and further glucosylated102, 
but the role of this disaccharide has not yet been elucidated and further experiments are 
needed to address this issue.  
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Fucosylation of TSR domain-containing proteins 
CSP is a highly-expressed protein and the main immunodominant antigen in the 
surface of sporozoites. It is essential for the sporozoite journey from the mosquito midgut 
to human hepatocytes155,157. The licensed RTS,S malaria vaccine is based in a fragment of 
CSP that contains the Repeat region and CSP’s TSR domain (Figure 19)202.  
 
Figure 19. RTS,S malaria vaccine. It derives from PfCSP protein and HBsAg. HBsAg, hepatitis B surface antigen; PfCSP, P. 
falciparum CSP. Adapted from Regules et al., Expert review of Vaccines, 2011202. 
A study from Coppi et al.157 proposed a model for CSP processing and function 
throughout the sporozoite migration from the mosquito midgut oocyst to the mammalian 
host liver157. The authors showed that CSP has two different conformations: one in which 
the N-terminal masks the TSR domain and an adhesive arrangement where the TSR domain 
is exposed. Interestingly the TSR domain exposition occurs during oocyst development in 
the mosquito and during hepatocyte invasion157.  
TRAP is another important sporozoite protein that has an essential role during 
parasite gliding motility and hepatocyte infection. Recently it was also confirmed that this 
protein is not only O-fucosylated but also C-mannosylated102. This was the first time that 
this posttranslational modification was reported in a parasite protein. GDP-Man, present in 
P. falciparum174, can be further transformed to Dol-P-Man by the action of a Dolichol-
phosphate mannose polypeptide 1 (DPM1), an enzyme annotated in the parasite 
genome203. Dol-P-Man acts as donor for the transference of Man residues during GPI-
anchor biosynthesis, but it is also the donor for the C-mannosylation modification204,205. The 
enzyme responsible for this posttranslational reaction is a C-mannosyltransferase, that was 
first described in C. elegans as DPY-19129. A putative homolog enzyme is present (based on 
identity (26%) and similarity (47%)) in P. falciparum genome. This annotated gene contains 
DPY-19-like predicted transmembrane domains and it is expressed in Plasmodium salivary 
gland sporozoites191. Similar to O-fucosylation, C-mannosylation seems to play a role in 
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protein secretion130, however, more research regarding the function and activity of the 
enzyme and the biological relevance of parasite C-mannosylation is required. 
Several studies highlight the importance of the protein structure of vaccine 
candidates due to its impact on antibody response and recognition206–208. CSP and TRAP 
are both used in malaria vaccine development and both present TSR domains209. The 
presence of O-fucose and/or other posttranslational modifications on the TSR domains may 
alter their immunogenicity. Not only the presence of the sugar residue, but also the protein 
folding, possibly mediated by the action of PoFUT2, could be important for eliciting a more 
precise and effective immune response. Therefore, testing the affinity of anti-CSP or anti-
TRAP antibodies against glycosylated or unglycosylated versions of CSP and/or TRAP would 
contribute to clarify the role of these posttranslational modifications present in key parasite 
antigens. 
To sum up, in this work we have been able to identify, for the first time, the different 
pools of sugar nucleotides present in the parasite, comprising GDP-Man, GDP-Fuc, UDP-
Gal, UDP-Glc and UDP-GlcNAc (Figure 17). We have also characterized the enzymes 
responsible for the biosynthesis of GDP-Fuc and showed preliminary evidences indicating 
the presence of a Fuc-containing glycan in the surface of the intraerythrocytic asexual 
stages of the parasite life cycle. Furthermore, we have contributed to the characterization 
of the O-fucosyltransferase that may be responsible for the addition of fucose in important 
Plasmodium proteins, such as CSP or TRAP. Nevertheless, several challenges concerning 
the glycobiology of P. falciparum remain to be addressed. Besides obtaining evidence of 
the glycosylation status of O-fucosylated proteins in PoFUT2 mutant parasites, the 
description of the O-fucose function in key parasite proteins and the characterization of 
other possible glycan modifications and glycosyltransferases in the parasite are important 











• Plasmodium falciparum intraerythrocytic stages contain five different sugar 
nucleotides that are developmentally regulated. These sugar nucleotides are: UDP-
glucose, UDP-galactose, UDP-N-acetylglucosamine, GDP-mannose and GDP-
fucose. 
• The parasites conserve the enzymes responsible for the synthesis of GDP-Fuc (i.e. 
GMD and FS). They localize in the cytoplasm of the asexual blood stages of the 
parasite, are active in vitro and are expressed along the intraerythrocytic cycle.  
• Homologs of the GDP-Fuc salvage pathway are not conserved in the parasite and 
it does not incorporate tritiated Fuc from the media. 
• After the disruption of GMD or FS genes, the pools of GDP-Fuc present in mutant 
parasites are comparable with the pools of the parental line. Thus, an alternative 
pathway not yet described for GDP-Fuc synthesis may be present. 
• A fucose-containing glycan is present in P. falciparum according to the binding of 
a fucose-specific lectin. This binding is abrogated in GMD mutant parasites. 
• GMD or FS disruption does not have any significant consequence regarding the 
growth, cell size and morphology of the parasite in culture. Therefore, the GDP-Fuc 
de novo pathway is not essential during asexual blood stages 
• P. falciparum expresses a protein O-fucosyltransferase (PoFUT2), but its disruption 
does not affect the growth of parasite blood stages 
• Truncation of PoFUT2, which may be the responsible for the fucosylation of 











 Summarized catalan version 
INTRODUCCIÓ 
Malària 
La malària mata un infant a l’Àfrica cada dos minuts. La malària és una de les 
malalties parasitàries més importants que afecta als humans. Aproximadament la meitat de 
la població mundial es troba en risc d’infecció. Està causada per un paràsit protozou del 
gènere Plasmodium i es transmet mitjançant una femella de mosquit del gènere Anopheles. 
Hi ha 5 espècies de Plasmodium diferents que poden infectar humans: Plasmodium 
falciparum, P. vivax, P. malariae, P. ovale i P. knowlesi1. Existeixen més de 400 espècies de 
mosquit Anopheles però només 70 són capaces de transmetre la malària i d’entre aquestes 
només 40 són les denominades espècies dominants2,3. P. falciparum i P. vivax són les dues 
espècies de paràsit responsables de la majoria de casos de malària. P. falciparum és 
l’espècie predominant a l’Àfrica i la responsable de la majoria de morts per malària4,5; 
mentre que P. vivax està més àmpliament distribuïda però el risc de mort per aquesta 
espècie és menor4,6.  
D’acord amb l’Organització Mundial de la Salut (OMS), l’any 2015 va haver-hi 241 
milions de casos nous i 429.000 morts causades per la malària, tot i aquesta dramàtica 
situació la incidència s’ha reduït de manera important des de l’any 20006. Àfrica és la regió 
on es troben la majoria de casos de malària (88%), sent els infants de menys de 5 anys i les 
dones embarassades les persones amb més risc de patir la malaltia. 
Entre set i quinze dies després de la picada d’un mosquit Anopheles infectat, els 
primers símptomes de la malaltia poden aparèixer i es classifiquen en malària no 
complicada o malària severa. La infecció amb el paràsit dóna lloc a un ampli rang de 
símptomes: des de manifestacions absents o molt lleus fins a la mort. La malària durant 
l’embaràs té efectes greus sobre la salut de la mare i del nadó, i és un cas important de 
mortalitat i morbiditat materno-infantil. 
Un elevat nombre de països està treballant per assolir l’eliminació de la malària16. 
La malària pot prevenir-se i tractar-se fent servir diferents intervencions cost-efectives. Les 
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principals comprenen: el control del vector, quimioprevenció i gestió apropiada dels casos 
de malària (incloent diagnòstic i tractament)17. 
El control del vector és un component essencial de la prevenció i el seu principal 
objectiu és disminuir la capacitat vectorial de la població local de mosquits. Pel que fa la 
prevenció, les estratègies per controlar els mosquits amb més impacte són l’ús de 
mosquiteres tractades amb insecticida de llarga durada i l’acció d’insecticides residuals a 
l’interior dels habitatges18. La quimioprevenció consisteix en el subministrament de 
medicaments antimalàrics a grups de risc com poden ser les dones embarassades o bé els 
infants5. El desenvolupament d’una vacuna eficaç seria una eina excel·lent per a l’eradicació 
de la malària. La vacuna RTS,S, que ofereix protecció modesta contra la malària clínica va 
ser aprovada recentment per l’Agència Europea del Medicament i l’OMS n’ha recomanat 
la implementació pilot a gran escala a diferents àrees d’entre 3 i 5 països6.  
Una diagnosis a temps i ben feta és una molt bona eina per a identificar si una 
persona està infectada pel paràsit de la malària i tractar-la de manera adequada i així evitar 
l’aparició i propagació de resistències. Els tests de diagnosis ràpids (RDT per les seves sigles 
en anglès) detecten antígens específics produïts pel paràsits i que estan presents a la sang. 
El tractament de la malària ha evolucionat amb el temps en funció de nous 
descobriments i de l’aparaició de resistències. La cloroquina va ser el primer tractament 
implementat per la OMS, però desafortunadament van sorgir resistències25. Després 
d’aquest entrebanc, medicaments alternatius com la sulfadoxina-pirimetamina, la 
mefloquina, l’amodiaquina i la quinina es van utilitzar com a monoteràpies, fet que va portar 
a l’aparició de soques resistents. El tractament de primera línia recomanat ara per l’OMS 
consisteix en una teràpia combinada d’artemisinina (ACT)30. Aquest tractament consisteix 
en utilitzar un derivat de l’artemisinina amb un antimalàric d’acció prolongada amb un 
mode d’acció diferent, per tal d’evitar l’aparició de resistències17. Tot i això, ja s’han 
confirmat regions al món on pacients han desenvolupat resistència als derivats de 
l’artemisinina, accentuant la necessitat de trobar nous fàrmacs32,33. 
Plasmodium falciparum 
El paràsit de la malària va ser descrit per primera vegada per Alphonse Laveran 
l’any 188035 i va ser guardonat pels seus descobriments amb el premi Nobel l’any 1907. 
L’any 1897 en William MacCallum va descriure la reproducció sexual del paràsit mentre 
estudiava la malària aviària37. I no va ser fins el 1898 que Ronald Ross va descobrir que el 
paràsit de la malària humana es transmetia mitjançant mosquits anofelins36. 
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L’any 1934 es va descobrir la cloroquina, que més tard es va establir com a 
antimalàric effectiu i segur. Uns anys més tard es van observar les propietats insecticides 
del DTT. Tots aquests descobriments van fer que l’OMS es decidís per impulsar una 
campanya per a l’eradicació de la malària. Va ser molt efectiva i entre els anys 1955 i 1972 
molts països van ser certificats com a lliures de malària. Durant aquest període però, també 
van aparèixer les primeres resistències contra la cloroquina25. La República de la Xina va 
promoure un programa per a trobar fàrmacs contra la malària i d’aquí en va sortir el 
descobriment de l’artemisinina i els seus derivats, pel qual Youyou Tu va guanyar un premi 
Nobel l’any 201529. Les teràpies combinades d’artemisinina són ara els tractaments de 
primera línia recomanats. L’any 2002 es va publicar la seqüenciació del genoma de la soca 
3D7 de P. falciparum39,40, i una mica més tard la de la resta de genomes d’altres espècies 
de Plasmodium. Aquests fets van obrir la porta a noves oportunitats d’estudi que lideressin 
el descobriment de nous fàrmacs i vacunes per lluitar contra la malària. 
P. falciparum té un cicle de vida complex que inclou estadis en dos hostes diferents: 
un mosquit i un humà. La transmissió entre humans i mosquits requereix la transició entre 
formes asexuals i sexuals dels paràsit. El cicle del paràsit comença quan una femella de 
mosquit Anopheles infectada inocula esporozoïts a l’hoste humà durant una ingesta de 
sang. Els paràsits migren a través de la pell fins que arriben al sistema circulatori i després 
al fetge. A l’interior del fetge els esporozoïts envaeixen un hepatòcit i al seu interior es 
desenvolupa i multiplica formant un esquizont hepàtic. Després d’aproximadament una 
setmana l’esquizont es trenca i allibera milers de merozoïts a la circulació sanguínia. Aquests 
merozoïts pre-eritrocítics envaeixen eritròcits i comencen diferents cicles de reproducció 
asexual. Durant el cicle asexual del paràsit, aquest passa per a diferents estadis anomenats: 
rings o anells, trofozoïts i esquizonts. Un petit percentatge d’aquests paràsits es diferencien 
en gametòcits mascle i femella. Aquestes formes sexuals son ingerides per una altra femella 
de mosquit Anopheles quan va a buscar aliment en un humà infectat. Els gametòcits 
maduren fins a gàmetes que fertilitzaran i maduraran a l’intestí del mosquit, formant un 
ooquinet infectiu que migra a través de la paret de l’intestí fins arribar a l’hemocel on el 
paràsit haurà evolucionat fins a oocist. A l’interior de l’oocist es formen milers d’esporozoïts 
que, després de la seva maduració, seran alliberats i viatjaran fins a les glàndules salivals 
del mosquit. Allà romandran llestos fins que tornin a ser injectats a un hoste humà i torni a 






La glicobiologia és un camp d’estudi molt ampli que comprèn l’estudi de qualsevol 
molècula que conté un carbohidrat a la seva estructura. Inclou l’estudi del metabolisme de 
carbohidrats i les estructures glicoconjugades (glicoproteïnes i glicolípids). Els monosacàrids 
són les unitats bàsiques dels carbohidrats i amb la unió de diferents monosacàrids es 
formen els oligosacàrids o polisacàrids. Les cadenes de polisacàrids presenten una enorme 
possibilitat de combinacions, però tot i així, no totes estan presents a la natura91. Els 
carbohidrats són una font important d’energia, però també tenen altres funcions 
biològiques importants com pot ser l’adhesió cèl·lula-cèl·lula, l’adhesió cèl·lula-matriu, 
control de qualitat de proteïnes i interaccions hoste-patògen, entre d’altres. Els 
glicoconjugats es defineixen com compostos que contenen una part sacarídica (mono o 
polisacarídica) unida covalentment a altres tipus de molècules com proteïnes o lípids, 
formant d’aquesta manera glicoproteïnes o glicolípids respectivament. Les funcions 
biològiques dels diferents glicans són molt diverses. Alguns d’ells són essencials pel 
desenvolupament, creixement o supervivència d’un organisme, mentre que alteracions en 
altres poden produir síndromes i malalties92,93. En altres casos, no es coneix la funció que 
desenvolupen a nivell cel·lular o a nivell d’organisme. 
Els paràsits protozous sintetitzen diferents glicoconjugats o proteïnes d’unió a 
glicans (lectines) que fan servir per a protegir-se i per interactuar i respondre a canvis en el 
seu ambient. Les interaccions hoste-patogen són crucials per la supervivència del paràsit i 
moltes d’aquestes es donen a través del reconeixement de carbohidrats94. El glicoma és el 
conjunt complet de glicosilacions que un organisme o cèl·lula produeix en un moment 
determinat. La descripció del glicoma del paràsit és un repte important que, juntament amb 
la determinació de la importància biològica de les diferents glicosilacions pot contribuir a 
la descripció de les interaccions hoste-patògen en malalties parasitàries94. P. falciparum 
conté diferents proteïnes glicosilades i lectines que tenen papers importants en la virulència 
del paràsit, la unió i la invasió de la cèl·lula hoste96,97. 
Els sucres nucleòtides són formes activades de monosacàrids. Aquests sucres 
nucleòtids són els donadors de les reaccions de glicosilació, que estan mediades per les 
glicosiltransferases. Existeixen dues vies principals de biosíntesi de sucres nucleòtids. Una 
via de novo que consisteix en la bioconversió d’un sucre o d’un sucre nucleòtid ja existent i 
una via de salvaging que inclou la fosforilació i una següent pirofosforilació del sucre91. Les 
reaccions de glicosilació consisteixen en la transferència de la part sacarídica d’un sucre 
nucleòtid a un acceptor específic mitjançant l’acció de glicosiltransferases98. Els acceptors 
específics poden ser oligosacàrids, proteïnes, lípids o fins i tot DNA. La majoria de les 
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glicosiltransferases es troben a la via reticle endoplasmàtic (RE) – aparell de Golgi, ja que 
moltes reaccions es donen en la via de secreció cel·lular91. La identificació i quantificació 
dels sucres nucleòtids presents a P. falciparum pot contribuir a la definició del perfil de 
glicosilació i el glicoma del paràsit.  
A continuació defineixo algunes de les glicosilacions presents o que, a partir d’altres 
estudis, podrien estar presents en el paràsit. 
- Àncores de glicosilfosfatidil inositol (GPI): 
Les àncores de GPI són una estructura glicolipídica que normalment ancora 
proteïnes a la superfície. Es sintetitzen a través d’una via de diferents passos seqüencials i 
després s’uneixen covalentment a l’extrem C-terminal de les proteïnes110. La part glicosídica 
de les àncores de GPI a P. falciparum ha estat descrita i consisteix en: (Manα1-2)Manα1-
2Manα1-6Manα1-4GlcN107,108. La síntesi de les àncores GPI és un procés complex que 
comença a la cara citoplasmàtica del RE i durant la síntesi donarà la volta fins al lumen del 
RE99. Els sucres nucleòtids involucrats en la síntesi d’aquesta glicosilació són la GDP-manosa 
(GDP-Man) i la UDP-N-acetilglucosamina (UDP-GlcNAc). Les àncores de GPI són els 
principals glicoconjugats descrits en els estadis intraeritrocítics del paràsit i s’encarreguen 
d’ancorar proteïnes clau a la membrana plasmàtica del paràsit103,115. Estan també presents 
en tots els estadis del paràsit: gametòcits, ooquinets i esporozoïts115. La proteïna CSP, 
essencial per als paràsits i utilitzada a la vacuna contra la malària, està unida a la superfície 
del paràsit a través d’una ancora de GPI117. Les àncores de GPI també s’han descrit com 
toxines que són capaces d’induir l’expressió de citoquines118. 
- N-glicosilacions 
La producció de N-glicans requereixen la presència d’un precursor oligosacàrid unit 
a lípids (LLO), que s’unirà al residu d’asparagina d’una proteïna mitjançant un enllaç N-
glicosídic. Una vegada sintetitzat el precursor LLO, el complex oligosacariltransferasa 
(complex OST) serà l’encarregat de transferir el LLO en bloc a la proteïna al RE91. La 
presència de N-glicosilacions a P. falciparum ha sigut controvertida durant temps, ja que 
resultats de diverses investigacions eren bastant diferents103,122,123. El genoma del paràsit 
conserva pocs dels gens responsables de dur a terme N-glicosilacions, fet que concorda 
amb la presència de N-glicans més curts que en altres espècies, només contenen dos 
residus de GlcNAC104. En eucariotes superiors les N-glicosilacions tenen un paper crucial en 
el plegament de proteïnes i també en l’estabilitat de proteïnes, solubilitat. I també poden 
ser importants per a l’antigenicitat i el reconeixement d’anticossos125,126. En canvi, les N-
glicosilacions a P. falciparum no s’han descrit completament i cal definir quina és la 
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importància biològica de la mida d’aquest tipus de modificació en el paràsit. Podrien 
desencadenar respostes immunes específiques ja que aquest tipus de glicoconjugats no es 
troba present en el glicoma humà99 
- C-manosilacions 
La C-manosilació consisteix en l’addició d’un residu de manosa en un aminoàcid 
triptòfan. El precursor d’aquesta reacció és la Dolichol-fosfat-manosa (Dol-P-Man). La 
particularitat d’aquesta glicosilació és el tipus d’enllaç glicosídic que es forma, ja que es 
dona entre dos àtoms de carboni, mentre que en els altres tipus de glicosilació es dóna 
entre un àtom de carboni i un àtom de nitrògen o oxigen91. Aquesta glicosilació es sol 
trobar en proteïnes que contenen dominis Thrombospondin type 1 repeats (dominis TSR)129–
131, un domini que està present en diverses proteïnes de Plasmodium. L’enzim responsable 
d’aquesta reacció és la manosiltransferas DPY19 i un homòleg d’aquest gen es troba 
conservat a tots els genomes de Plasmodium. La importància biològica d’aquesta 
modificació postraduccional cal que sigui estudiada. 
- O-glicosilacions 
Les O-glicosilacions consisteixen en la unió covalent d’un sucre al grup hidroxil (OH) 
d’una serina o d’una treonina mitjançant un enllaç O-glicosídic. En eucariotes superiors el 
tipus d’O-glicosilació més abundant consisteix en la unió d’un residu de N-
acetilgalactosamina (GalNAc), que després s’allarga amb altres sucres i genera les 
anomenades mucines91. Tot i això existeixen altres tipus d’O-glicosilació en cèl·lules 
eucariotes com per exemple l’O-fucosilació, la O-manosilació o O-galactosilació entre 
d’altres91. Malgrat alguns estudis controvertits, l’O-glicosilació no s’ha descrit mai clarament 
al paràsit (excepte l’O-fucosilació, veure a continuació).  
La conservació de gens homòlegs per la via de síntesi de novo de la GDP-Fuc (GMD 
i FS) suggereixen la presència de glicans fucosilats en el paràsit. La O-fucosilació consisteix 
en l’addició de una fucosa provinent de la GDP-Fuc a un grup OH d’un residu de serina o 
treonina. La O-fucosilació es troba en dominis Epidermal Growth Factor (EGF) i en dominis 
TSR. Tot dos motius estan fucosilats a través d’enzims PoFUT (proteïna o-fucosiltransferasa). 
Aquests enzims són capaços de distingir entre dominis ben plegats o no ben plegats, 
suggerint que tenen un paper important en mecanismes de plegament i de control de 
qualitat136. PoFUT2 és l’enzim encarregat de fucosilar els dominis TSR136. Aquests dominis 
es troben presents a diferents proteïnes de Plasmodium que són possibles acceptors 
d’aquesta O-glicosilació. Els dominis TSR són motius petits rics en cisteïnes i que conserven 
3 ponts disulfur. Aquests dominis estan relacionats amb diferents funcions importants com 
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per exemple la regulació de la matriu extracel·lular i les interaccions cèl·lula-cèl·lula145. La 
fucosilació d’aquests dominis es dona en la seqüènca consens CX2(S/T)CX2G144,145 (On C és 
cisteïna, X pot ser qualsevol aminoàcid, S correspon a la Serina, T a treonina i G a glicina). 
PoFUT2 pot fucosilar només dominis que están correctament plegats, suggerint l’habilitat 
de la proteïna per reconèixer les dues formes (ben plegada o no ben plegada) del domini 
TSR143. El silenciament de PoFUT2 o la reducció del sucre nucleòtid donador (GDP-Fuc) 
resulta en problemas de secreció de proteïnes, i knockouts de PoFUT2 en ratolí tenen 
conseqüències letals145–147. Els residus d’O-Fuc dels dominis TSR es poden allargar amb un 
residu de glucosa mitjançant una β-1,3 glicosiltransferasa101. 
Els dominis TSR estan presents en diferents proteïnes del paràsit que s’expressen al 
llarg de tot el cicle del paràsit. Entre aquestes trobem: MTRAP, CTRP, CSP i TRAP, que es 
descriuen a continuació. Altres proteïnes del paràsit que contenen dominis TSR són SPATR, 
TRAMP, TREP o TLP, però aquestes han estat menys estudiades. 
Merozoite TRAP (MTRAP): és una proteïna de la família TRAP relacionada amb 
gliding motility, un mecanisme de transport que depen de substrat150. Està expressada als 
estadis sanguinis tant sexuals com asexuals del paràsit. S’ha descrit que té un paper 
important en la sortida del paràsit sexual o gàmeta de l’interior dels eritròcits152. 
Circumsporozoite and TRAP Related Protein (CTRP): és una proteïna expressada en 
els ooquinets de Plasmodium i que es localitza en un dels orgànuls del paràsit, les 
micronemes153. S’ha descrit el seu paper en la invasió de l’epiteli de l’intestí del mosquit.84 
Circumsporozoite Protein (CSP): és una proteïna molt conservada en totes les 
espècies de Plasmodium. S’expressa en els esporozoïts del paràsit i es troba ancorada a la 
superfície mitjançant una àncora de GPI155. Té un paper essencial en la invasió de les 
glàndules salivals del mosquit així com la invasió dels hepatòcits157. S’ha descrit recentment 
que el domini TSR d’aquesta proteïna està fucosilat102. 
Thrompospondine Related Anonymous Protein (TRAP): és una proteïna essencial 
involucrada en la invasió i motilitat dels esporozoïts158. L’O-fucosilació i C-manosilació 







HIPÒTESI I OBJECTIUS 
L’estudi de la glicobiologia de paràsits pot obrir noves línies de recerca que portin 
al descobriment de nous fàrmacs antiparasítics selectius o a candidats a vacunes, a través 
de la identificació de noves dianes essencials per als paràsits.  Tenint en compte els 
glicoconjugats descrits en altres estudis fets amb Plasmodium, la presència de GDP-Fuc no 
s’esperava. Malgrat això, els gens de la ruta metabòlica per a la síntesi de novo de GDP-Fuc 
a P. falciparum estan conservats al seu genoma i al de totes les espècies de Plasmodium 
seqüenciades. A més a més, els paràsits també conserven en el genoma una putativa 
proteïna O-fucosyltransferasa (PoFUT2), que és la responsable de l’addició de fucosa a 
dominis TSR. Aquests dominis estan presents en proteïnes de Plasmodium que tenen 
funcions clau en diferents estadis del paràsit. Tenint en compte tota aquesta informació la 
nostra hipòtesi és que P. falciparum té un mecanisme de O-fucosilació actiu. Per explorar 
aquesta hipòtesi, els objectius d’aquesta tesis doctoral són: 
• Identificar i quantificar el contingut de sucres nucleòtids present en els estadis 
intraeritrocítics de P. falciparum 
• Confirmar l’activitat enzimàtica in vitro de PfGMD i PfFS, els enzims responsables 
de la síntesi de GDP-Fuc en els estadis asexuals del paràsit. 
• Descriure la importància biològica de PfGMD i PfFS, tot creant paràsits mutants 
sense aquests enzims i estudiant el seu fenotip 
• Determinar la funció de la proteïna O-fucosyltransferasa 2 (PoFUT2) de P. 
falciparum creant mutants complets per a aquest gen i caracteritzant el fenotip a 





Article 1: “Biosíntesi de GDP-fucosa i altres sucres nucleòtids als estadis 
intraeritrocítics de Plasmodium falciparum” 
Antecedents: 
Les àncores de GPI representen la major part de modificacions de carbohidrats que 
s’han descrit a la superfície de P. falciparum. Moltes de les proteïnes que estan unides a 
aquestes àncores són essencials per a la invasió i la virulència del paràsit. Recenment s’ha 
descrit la presència de N-glicosilacions als estadis intraeritrocítics del paràsit. Fins ara 
l’existència d’O-glicosilacions en el paràsits no ha estat demostrada. Els sucres nucleòtids 
són formes activades dels sucres i que han estat produïdes per la cèl·lula. Són intermediaris 
essencials per a les reaccions de glicosilació. Poden sintetitzar-se mitjançant una via de novo 
o bé mitjançant una via de rescat. En el genoma de P. falciparum, així com en el de la resta 
d’espècies de Plasmodium seqüenciades es poden predir els gens implicats en la síntesi de 
novo de la UDP-N-acetilglucosamina, GDP-manosa, GDP-fucosa i UDP-glucosa. Aquesta 
idea suggereix que el seu manteniment es deu a la importància biològica d’aquestes vies i 
també l’existència de glicosilacions on aquests sucres nucleòtids són els donadors 
Objectiu: 
Tenint en compte la falta d’estudis en aquest camp volem quantificar el contingut 
de sucres nucleòtids present en el paràsit i caracteritzar els enzims responsables de la síntesi 
de novo de la GDP-Fuc anotats en el genoma de Plasmodium 
Resultats: 
• Mitjançant l’espectrometria de masses, hem identificat i quantificat, per primera 
vegada, el contingut de sucres nucleòtids present al paràsit, que són: UDP-
galactopiranosa, UDP-glucosa, UDP-N-acetilglucosamina, GDP-manosa i GDP-
fucosa 
• El paràsit no és capaç d’incorporar fucosa tritiada ([3H]-Fuc) del medi, indicant que 
la principal font de GDP-Fuc del paràsit és mitjançant la síntesi de novo 
• Els gens encarregats de la síntesi de GDP-Fuc, que són GMD i FS, s’expressen al 
llarg de tot el cicle asexual del paràsit, són actius in vitro i es localitzen al citoplasma 
del paràsit. 
• Els esquizonts del paràsit expressen una proteïna homòloga a la proteina O-
fucosiltransferasa 2 (PoFUT2). A més a més, extractes d’esquizonts de P. falciparum 




El paràsit P. falciparum conté diferents sucres nucleòtids que es corresponen amb 
el manteniment en el genoma de vies metabòliques encarregades de la seva síntesi. La 
presència de GDP-fucosa, la demostració de l’activitat in vitro dels enzims encarregats de 
sintetitzar-la així com l’expressió d’una fucosiltransferasa suggereixen la presència d’un glicà 




Article 2: “La disrupció de la síntesi de novo de GDP-fucosa suggereix la presència 
d’un nou glicoconjugat que conté fucosa en els estadis asexuals de Plasmodium” 
Antecedents: 
Els glicoconjugats a la superfície cel·lular són mediadors important de les 
interaccions hoste-patògen. La presència d’un pool de GDP-fucosa i l’expressió d’una 
fucosiltransferasa suggereixen que aquest sucre nucleòtid pot estar implicat en la 
modificació post traduccional dels dominis TSR, dominis presents en proteïnes clau pel 
desenvolupament del paràsit de la malària. Recentment s’ha descrit la presència d’O-
glicosilacions i C-manosilacions als esporozoïts del paràsits. 
Objectiu: 
Mitjançant la disrupció dels gens implicats en la biosíntesi de novo de GDP-fucosa 
(GMD i/o FS) volem caracteritzar i descriure la importància biològica d’aquesta via 
metabòlica. 
Resultats: 
• La disrupció de GMD i FS és possible als estadis asexuals del paràsit i aquesta no 
afecta el creixement in vitro ni la morfologia i mida del paràsit. 
• El contingut de GDP-fucosa, així com el dels altres sucres nucleòtids no es veu 
significativament afectat a causa de la disrupció de GMD i FS. 
• La síntesi d’un glicà que conté fucosa s’atura en els paràsits que tenen els gens 
GMD i FS disruptats. Això queda demostrat per la disminució del marcatge de la 
lectina d’unió a fucosa Ulex europaeus agglutinin 1 (UEAI) a la superfície del paràsit. 
Conclusió: 
La possibilitat de truncar els gens responsables de la síntesi de novo de GDP-fucosa 
ens permet concloure que aquesta via metabòlica no és essencial per al paràsit. El 
manteniment del contingut de sucres nucleòtids en els paràsits mutants suggereix que hi 
ha una via alternativa d’obtenció de GDP-fucosa que encara no ha estat descrita. Tot i això 
la disrupció d’aquesta via metabòlica sí que atura la síntesi del glicà que conté fucosa i que 




Treball no publicat: Paràsits Plasmodium sense la maquinària d’O-fucosilació són 
capaços de completar el cicle de vida en humans i ratolins. 
Antecedents: 
Els dominis TSR són dominis petits (entre 50 i 60 aminoàcids) rics en cisteïnes i que 
contenen 3 ponts disulfurs conservats. Tenen papers importants en l’adhesió cel·lular i en 
la motilitat. Els paràsits del gènere Plasmodium expressen, al llarg de tot el cicle, diferents 
proteïnes amb dominis TSR; proteïnes amb papers claus en el reconeixement hoste-cèl·lula, 
en motilitat i en invasió. Entre aquestes proteïnes trobem la Circumsporozoite protein (CSP), 
la Thrombospondin Related Anonymus protein (TRAP) entre d’altres. S’ha desmostrat que 
anticossos contra aquestes proteïnes inhibeixen la invasió i paren la progressió del cicle del 
paràsit. A més a més, són importants candidats a vacunes. De fet la vacuna contra la malària 
amb llicència i recomenada per la OMS, RTS,S es basa en la proteïna CSP, que conté un 
domini TSR a l’extrem C-terminal.  
S’ha demostrat que els dominis TSR són O-fucosilats per la proteïna PoFUT2 i que 
a més a més es poden allargar amb un residu de glucosa, generant un disacàrid O-linkat. 
Aquesta modificació és important per la secreció de proteïnes que contenen aquests 
dominis. Un estudi recent ha demostrat que les proteïnes CSP i TRAP estan ambdues 
fucosilades en els seus dominis TSR. El genoma de P. falciparum conserva un homòleg de 
la proteïna PoFUT2, el paràsit sintetitza GDP-fucosa, inidicant que PoFUT2 pot ser 
l’encarregada de dur a terme aquesta modificació post-traduccional. 
Objectius: 
Crear mutants que no continguin la proteïna PoFUT2 en el paràsit de la malària 
humana i el model de ratolí, P. falciparum i P. berghei respectivament. 
Caracteritzar els mutants resultats al llarg de tot el cicle del paràsit, tant en els estadis 
sanguinis com en els estadis que es desenvolupen en els mosquits. 
Resultats: 
• La creació dels paràsits mutants de la proteïna PoFUT2 ha estat possible en el 
paràsit de la malària humana i en el del model de ratolí. Això indica que aquest gen 
no és essencial per al desenvolupament del paràsit. 
• Els paràsits mutants no presenten cap tipus d’afectació en quant al creixement en 
els estadis asexuals intraeritrocítics. 
127 
 
• Les línies del paràsit que no contenen la proteïna encarregada de dur a terme la 
fucosilació són capaces d’infectar mosquits i la producció dels oocists és normal 
comparada amb la soca no mutant. 
• Els esporzoïts de les soques de paràsit mutant poden infectar les glàndules salivals 
del mosquit i a més són capaces de re-infectar els ratolins. 
Conclusió: 
La disrupció del gen PoFUT2 no té un efecte obvi sobre el fitness del paràsit, ja que 
tant els estadis asexuals com els estadis que es desenvolupen en el mosquit creixen de 
manera comparable. L’efecte de la no presència de residus de fucosa en proteïnes 
essencials per al paràsit cal que s’estudiï amb més profunditat, ja que podria tenir un paper 





La malària és un dels principals problemes de salut que afecta als humans en països 
en desenvolupament. Cal seguir fent esforços per tal de poder arribar a l’objectiu d’eradicar 
la malària. La glicobiologia és l’estudi dels procesos relacionats amb els carbohidrats i els 
glicoconjugats. Descriure la glicobiologia del paràsit causant de la malària i la seva 
importancia pel cicle d’aquest, obrirà noves portes per a la identificació de noves dianes 
terapèutiques i per a vacunes. 
Sucres nucleòtids a P. falciparum.  
Estudis previs no havien descrit la presencia de fucosa en el paràsit de la 
malària97,103,104,172,173. En aquesta tesi es descriu la presencia de GDP-Fuc i d’altres sucres 
nucleòtids presents en el paràsit, avessant més llum a la importancia d’aquests precursors 
en el paràsit. Per tant, el meu primer treball descriu evidències de la presencia de diferents 
sucres nucleòtids en els estadis sanguinis de P. falciparum, incloent GDP-Fuc174. Aquesta 
troballa ha permès millorar la descripció de les vies metabòliques involucrades en la síntesi 
d’aquests precursors. 
La identificació de UDP-galactosa (UDP-Gal) no es corresponia amb la falta aparent 
de l’activitat enzimàtica responsable de la síntesi d’aquest sucre nucleòtid. L’enzim UDP-
Glc 4-epimerasa (GALE)175, involucrat en la síntesi de UDP-Gal a través de l’epimerització 
de UDP-Glc, no es pot identificar en el genoma del paràsit mentre que si que el trobem en 
altres paràsits99. Un homòleg de l’enzim UTP-glucosa 1-fosfat uridiltransferasa (UGP) 
(PF3D7_0517500) està anotat al genoma del paràsit. Altres paràsits com L. major presenten 
una activitat similar amb un rang més ampli de substrats (enzim UDP-sucre pirofosforilasa 
(USP))116, podent fer servir altres sucres177,178. Per tant una possible via de síntesi de UDP-Gal 
a P. falciparum seria a través de PF3D7_0517500, que presenta similaritats amb l’enzim USP. 
Altres treballs s’estan realitzant per tal de caracteritzar aquesta activitat enzimática (Cova et 
al., en preparació). El destí del pool de UDP-Gal a P. falciparum no es coneix, però alguns 
estudis han suggerit la presencia de α-galactosilacions als estadis interaeritrocítics del 
paràsit181,183. Els estudis més recents descriuen evidències indirectes de la presencia d’α-
galactosilacions i a més a més també desmostren que respostes immunes en contra 
d’aquests glicans confereixen protecció contra la malària170.  
Les nostres dades també demostren l’esperada presència de UDP-GlcNAc als 
estadis sanguinis del paràsit174. Hi ha dues vies de síntesi de UDP-GlcNAc: una via de novo 
i una de salvaging. Les dues vies necessiten però, l’activitat glucosamina-6-fosfat N-
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acetiltransferasa (GNA), un enzim que no s’ha pogut identificar a P. falciparum tot i que 
s’ha descrit completament a altres organismes184–186. La presencia del sucre nucleòtid indica 
que aquesta activitat ha d’estar present en el paràsit. UDP-GlcNAc és donador a les 
reaccions de síntesi d’àncores GPI i en les de N-glicosilació104. Per tant la síntesi d’aquest 
sucre nucleòtid és un proces important pel paràsit ja que aquestes glicosilacions són 
essencials per aquest114. Al nostre laboratori s’està treballant  per esbrinar l’activitat GNA de 
Plasmodium, així com la d’altres paràsits apicomplexos (Cova et al., en preparació). 
GDP-Fuc a P. falciparum 
El genoma de P. falciparum codifica els enzims necessaris per a la síntesi de novo 
de GDP-fucosa. A més a més no conté gens homòlegs per a la via de salvaging. La 
descripció del pool de GDP-Fuc en el paràsit concorda amb el manteniment dels enzims i 
la desmostració de la seva activitat in vitro174. La incorporació de [3H]-GDP-Fuc en assaigs 
lliures de cèl·lula en extractes de paràsits suggereixen la presencia d’una activitat 
fucosiltransferasa i de gliconconjugats fucosilats. La presència d’aquest conjugat es va 
demostrar de manera indirecta en el meu següent treball187. La disrupció de GMD va reduir 
la unió d’una lectina específica a fucosa. Però, de manera sorprenent, el truncament 
d’aquest gen no va afectar de manera significativa el pool de GDP-Fuc present a la cèl·lula, 
suggerint una via altrernativa de generació d’aquest sucre nucleòtid, tot i que no vam ser 
capaços de demostrar-ho mitjançant la incorporació de Fuc o GDP-Fuc tritiada. S’han 
descrits mecanismes de difusió passiva en el paràsit, essent una possibilitat per a l’obtenció 
de GDP-Fuc188,189. Tot i que la via de síntesi de GDP-Fuc de novo no sembla ser la única font 
d’aquest sucre nucleòtid, la seva disrpució sembla esta apagant la síntesi de glicoconjugats 
fucosilats, però sense cap altra cost obvi pel paràsit. 
El metabolisme de la fucosa ha resultat ser essencial en altres paràsits protozous 
com T. brucei. Un mutant condicional de GMD en aquest paràsit va fer disminuir la quantitat 
de GDP-Fuc a l’organisme i els paràsits van deixar de crèixer. Tot i això els autors no van 
ser capaços de trobar el gliconjugat109. T. gondii, així com T. brucei tampoc té via de 
salvaging de GDP-Fuc. En un article recent, Bandini et al. van sugerir que la via de novo és 
esencial pel paràsit190. Tot i això, la via de novo de la GDP-Fuc a P. falciparum no és essencial 
pels estadis asexuals del paràsit187, però pot ser que ho sigui en altres estadis que no hem 
pogut estudiar. 
La presumpta presència d’un glicoconjugat fucosilat a la superficie del paràsit 
necesita de l’activitat fucosiltransferasa187. L’únic candidat identificat en el genoma del 
paràsit és PoFUT2 (PF3D7_0909200), que s’expressa en els estadis madurs del cicle 
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intraeritrocític del paràsit174. A més a més, anàlisis proteòmiques d’esporozoïts de P. 
falciparum van detectar aquesta fucosiltransferasa191. PoFUT2 és l’enzim responsable de la 
O-fucosilació dels dominis TSR, presents en diverses proteïnes del paràsit161. Algunes 
d’aquestes proteïnes que contenen aquest domini tenen papers importants i s’han definit 
com a essencials per al paràsit. Recentment s’ha descrit l’O-fucosilació de dues d’aquestes 
proteïnes, CSP i TRAP102. Tota aquesta informació, suggereix la presencia d’un mecanisme 
d’O-fucosilació. Per tal d’avaluar-ne la seva importància vam generar un KO de PoFUT2 
per estudiar-ne el fenotip.  La viabilitat dels KO de PoFUT2 en P. falciparum i en P. berghei 
van revelar que la maquinària d’O-fucosilació no és essencial pel desenvolupament del 
paràsit. A més a més els mutants van ser capaços de completar tot el cicle a través dels 
mosquits i d’infectar hepatòcits, indicant que la manca de PoFUT2 no afecta 
significativament als papers claus que tenen les proteïnes que contenen dominis TSR. Per 
tal de confirmar la funció de PoFUT2 al paràsit, estem investigant, mitjançant mètodes 
proteòmics, l’estat de glicosilació de proteïnes que es coneix que están fucosilades, com 
CSP o TRAP. 
PoFUT2 en el plegament de proteïnes i en el control de qualitat 
Els glicans no només tenen un paper important en les interaccions cèl·lula-cèlula, 
sinó que també estan involucrats en el plegament de proteïnes i en control de qualitat192. 
En eucariotes superiors, els N-glicans són reconeguts per chaperones del RE que ajuden 
en el correcte plegament de proteïnes que s’estan formant91. PoFUT1, que fucosila dominis 
EGF i es troba al RE, pot discernir entre dominis ben plegats o mal plegats. S’ha descrit que 
la PoFUT1 té activitat chaperona a més a més d’acitivitat fucosiltransferasa194,195, i que 
aquestes dues activitats són independents l’una de l’altre196. PoFUT2, que també es localitza 
al RE pot tenir algun paper similar en mecanismes de control de qualitat. Diferents estudis 
han demostrat que la manca de PoFUT2 resulta en problemes de secreció de proteïnes145 i 
el KO d’aquesta proteïna en ratolins no és viable147. Totes aquestes informacions 
suggereixen un paper en el correcte plegament i secreció de proteïnes i en control de 
qualitat136. Un model sobre el funcionament de PoFUT2 descriu el mecanisme pel qual 
aquest enzim actua sobre les proteïnes136. Un domini TSR desplegat està en equilibri amb 
diferents intermediaris de plegament, amb les cisteïnes emparellades de manera incorrecta. 
PoFUT2 només reconeixerà i fucosilarà, aquells intermediaris que estiguin correctament 
aparellats (C1-C5 i C3-C4 o C1-C5 i C2-C6), desplaçant l’equilibri cap a la forma totalment 
plegada i fucosilada del domini TSR. Aquest model suggereix que l’activitat 
fucosiltransferasa i l’activitat chaperona no són independents136. Els nostres resultats 
demostren que la disrupció de PoFUT2 no afecta el plegament i secreció de proteïnes de 
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Plasmodium que contenen dominis TSR en condicions de laboratori. Tot i això l’O-
fucosilació pot ser important pel control de qualitat quan els paràsits es troben sota 
diferents tipus d’estrés del RE, com és el cas de glicosiltransferases involucrades en sistemes 
de control de qualitat de proteïnes similars198,199. Per tant, més experiments al voltant 
d’aquesta idea podrien ajudar a determinar el rol de PoFUT2 durant el plegament i control 
de qualitat de proteïnes. 
Els residu d’O-Fuc als dominis TSR poden ser allargats mitjançant l’activitat d’una 
β1,3-glicosiltransferasa101. Aquest enzim, responsable de l’elongació amb glucosa en 
humans, també intervé en un mecanisme de control de qualitat, i deficiències en aquest 
enzim causen diferents síndromes en humans200. Homòlegs d’aquest gen no estan anotats 
al genoma de Plasmodium, pero anàlisis BLAST amb l’enzim humà van identificar una 
possible proteïna present a la superfície dels eritròcits infectats (parasite-infected 
erythrocyte surface protein 1 or PIESP1; (PF3D7_0310400))101,201. S’ha demostrat, que 
proteïnes del paràsit amb aquests dominis es troben fucosilades i també glicosilades102, 
però el rol d’aquest disacàrid a Plasmodium no s’ha descrit encara.  
Fucosilació de proteïnes que contenen dominis TSR 
CSP és una proteïna altament conservada i expressada i és el principal antígen 
immunodominant a la superficie del paràsit. És una proteïna essencial per la migració de 
l’esporozoït des de l’intestí del mosquit fins a l’hepatòcit humà155,157. A més a més, la vacuna 
de la malària RTS,S es basa en un fragment que conté el domini TSR d’aquesta proteïna202. 
Un estudi de Coppi et al. va proposar un model pel processament i la funció d’aquesta 
proteïna157. Els autors mostren que CSP té dues conformacions: una en que l’extrem N-
terminal emmascara el domini TSR i una conformació adhesiva on el domini TSR està 
exposat. Justament l’exposició del domini TSR ocorre durant el desenvolupament de l’oocist 
al mosquit i durant la invasió de l’hepatòcit157. 
TRAP és un altra proteïna important de l’esporozoït que té un paper essencial per 
a la motilitat del paràsit i la infecció de les cèl·lules del fetge. S’ha confirmat que aquesta 
proteïna a més d’estar fucosilada, també està C-manosilada102, era la primera vegada que 
es describia aquest tipus de glicosilació en proteïnes del paràsit. Un posible enzim 
responsable de l’activitat manosiltransferasa està present en el genoma del paràsit, però 
calen més estudis per desxifrar l’activitat d’aquest enzim i la importancia biológica de la 
modificació postraduccional. 
Diferents estudis resalten la importància de coneixer l’estructura dels candidats a 
vacunes, degut a l’efecte que té aquesta en la resposta i reconeixement d’anticossos206–208. 
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CSP i TRAP es fan servir en el desenvolupament de vacunes per a la malària i les dues 
presenten dominis TSR209. La presència d’O-fucosilacions i altres modificacions en els 
dominis TSR poden alterar la immunogenicitat. Per tant, avaluar l’afinitat d’anticossos anti-
CSP o anti-TRAP contra versions de CSP o TRAP glicosilades o no glicosilades pot clarificar 
el rol d’aquestes modificacions en antígens claus del paràsit.  
Per resumir, en aquest treball hem pogut identificar per primera vegada, els 
diferents pools de sucres nucleòtids presents en el paràsit. També hem pogut caracteritzar 
els enzims responsables de la biosíntesi de GDP-Fuc i mostrar evidències preliminars que 
indiquen la presència d’un glicà que conté fucosa a la superfície dels estadis sanguinis del 
paràsit. A més a més, hem contribuit a la caracterització de la O-fucosiltransferasa que pot 
ser responsable de l’addició dels residus de fucosa als dominis TSR de proteïnes importants 
com poden ser TRAP o CSP. Tot i això queden reptes importants relacionats amb la 
glicobiologia del paràsit. A més d’obtenir evidències de l’estat de glicosilació dels mutants 
de PoFUT2; la descripció de la funció de l’O-fucosa en proteïnes clau i la caracterització 






• Els estadis intraeritrocítics de Plasmodium falciparum contenen cinc sucres 
nucleòtids diferents: UDP-glucosa, UDP-galactosa, UDP-N-acetylglucosamina, 
GDP-manosa, i GDP-fucosa 
• Els paràsits conserven els enzims responsables de la síntesi de GDP-fucosa (GMD i 
FS). Es localitzen al citoplasma dels estadis asexuals del paràsits, són actius in vitro i 
s’expressen al llarg de tot el cicle intraeritrocític. 
• Homòlegs de la via de salvaging de GDP-fucosa no estan conservats en el genoma 
del paràsit i aquest no incorpora Fuc del medi. 
• Tot i la disrupció dels gens GMD i/o FS, el pool de GDP-Fuc present en els paràsits 
mutants són comparables amb el contingut de GDP-Fuc de la soca salvatge. Per 
tant, una via alternativa encara no descrita deu estar present en el paràsit. 
• Un glicà que conté fucosa és present a P. falciparum tenint en compte la unió d’una 
lectina d’unió específica a fucosa. Aquesta unió desapareix en els mutants de GMD. 
• La disrupció de GMD i FS no té cap conseqüència significativa pel creixement, la 
mida i la morfologia del paràsit en cultiu. Per tant, la via de síntesi de novo de la 
GDP-Fuc no és essencial durant els estadis sanguinis del paràsit. 
• P. falciparum expressa una proteïna O-fucosiltransferasa (PoFUT2) durant els 
estadis sanguinis del paràsit. La seva disrupció no afecta el creixement dels estadis 
intraeritrocítics 
• El truncament de PoFUT2, l’enzim que podria ser el responsable de la fucosilació 
de proteïnes clau de Plasmodium, no altera el desenvolupament del paràsit durant 
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